



MALABAR CANCER CENTRE
[Postgraduate Institute of Oncology Sciences & Research]
THALASSERY



HOSPITAL BASED CANCER REGISTRY REPORT 2022
Funded by NCDIR, ICMR



Published on August 2024

ACKNOWLEDGEMENT

The Hospital Based Cancer Registry of Malabar Cancer Centre expresses its sincere thanks and gratitude to the following Institutions/Departments/Individuals for supporting and promoting the activities of the Registry.

- National Cancer Registry Programme, Indian Council of Medical Research, Bangalore
- Medical Records Division, Malabar Cancer Centre, Thalassery
- Department of Radiation Oncology, Malabar Cancer Centre, Thalassery
- Department of Clinical Hematology & Medical Oncology, Malabar Cancer Centre, Thalassery
- Department of Pathology, Malabar Cancer Centre, Thalassery
- Department of Surgical Oncology, Malabar Cancer Centre, Thalassery
- General Administration, Malabar Cancer Centre, Thalassery

FROM DIRECTOR'S DESK



I am privileged to present our 13th Hospital Based Cancer Registry (HBCR) annual report, HBCR 2022. Malabar Cancer Centre (Postgraduate Institute of Oncology Sciences and Research) is involved actively in cancer control activities of the government of Kerala and its responsibility as a policy suggesting institution depends largely on its epidemiological studies and cancer registry. HBCR reports of 13 years provides the magnitude and patterns of cancer in the region and the referral pattern to the institution. The oncologists and researchers can effectively utilize these statistics to plan their researches. Apart from previous years, in 2022 thyroid cancer was the second leading cancer in females after breast cancer. This may be due to the well establishment of the Nuclear medicine department of MCC-PGIOSR and its evolution as an advanced and aggressive surgical centre. This necessitates the need to correlate our PBCR reports of this region to understand the actual trend of thyroid cancer. The highlights of this HBCR Annual Report are as follows. A total of 6059 new cancer patients were registered at MCC-PGIOSR during the year 2022. Among them 3130 (51.7%) were males and 2929 (48.3%) were females. Except thyroid cancers the leading cancers of this year also shows approximately the same patterns as in previous years. The number and proportion of leading cancers in males are as follows. Lung (17%), Stomach (6.1%), Mouth (6%), Liver (5.9%) and Rectum (5.2%). Number of cases and proportion of leading cancers in females as follows. Breast (29.2%), Thyroid (8.6%), Cervix (5.8%), Ovary (5.8%) and Corpus Uteri (4.8%). Total proportion of tobacco related cancer (TRC) relative to all sites are 43.3% and 12.3% among males and females respectively. The support and encouragement received from the Director and team of National Centre for Disease Informatics and Research (NCDIR), Bangalore, and the Department of Health and family welfare, Government of Kerala are invaluable and the gratitude is expressed. Under the leadership of Dr. Saina, Dr. Bindu and Dr. Ratheesan with their team made this report a reality and they deserve appreciation for their efforts and sincerity.

I wish and hope this report will strongly support young researchers and administrators those who are involved in oncology related fields.

Dr. Satheesan Balasubramanian

DIRECTOR

I am glad to bring forth the thirteenth report of Hospital based cancer registry of the institution.

Hospital-based cancer registries maintain data on all patients diagnosed or treated for cancer at a particular facility. The focus of the hospital-based cancer registry is on clinical care and hospital administration.

Reducing the burden of this disease is a great and noble cause that involves many programmes, including a comprehensive database of all cancer cases. This database is what is referred to as a tumour registry. The importance of a tumour registry lies in the collection of accurate and complete cancer information that can be used for population-based research, public health programme planning, evaluation of current practices and patient care improvement. The information helps health professionals to better understand the disease and to use resources effectively for the prevention. The data can be analysed to compare the frequency and types of cancer between years, find patterns that identify possible risk factors and predict future incidence.

We also wish to extend our appreciation & acknowledge, National Centre for Disease Informatics and Research (NCDIR), ICMR, Bengaluru for their financial & technical assistance.

I would like to express my sincere gratitude to our Director, Dr. Satheesan Balasubramanian, without whose support, guidance & encouragement we would not have reached so far. The registries and all our team members deserve special thanks for their dedicated work

Dr. Saina Sunilkumar
Principal investigator
Hospital Based Cancer Registry



TABLE OF CONTENTS

SI. No	Contents	Page No
I	Introduction	6-9
	Organisation	6
	Department of Cancer Registry & Epidemiology	7
	Hospital Based Cancer Registry	8
	National Cancer Registry Programme	9
II	Summary of Results	9-24
	Patterns of Cancer Registration	10
	District wise Cancer Registration	11
	Leading Site of Cancers	12
	Cancer Sites by Age and Gender	14
	Tobacco Related Cancers	17
	Method of Diagnosis	18
	Clinical Extent of Disease	19
	Cancer Directed Treatment	20
	Childhood Cancers	22
	Demographic Details	24
III	Detailed Information: Diagnostic, Clinical & Demographic	25-49
IV	Detailed Information -MCC	51-53
	New/Old Cases	52
	Systemwise Cancers	52
	Habits & Systemwise Cancer	53
V	Ten Leading Cancers – Irrespective of Sex	54-83
	Breast	54
	Lung	57
	Thyroid	60
	Rectum	63
	Mouth	66
	NHL	69
	Stomach	72
	Liver	75
	Colon	78
	Tongue	81
VI	References	84

INTRODUCTION

Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighbouring parts of Karnataka and Tamilnadu states and Union Territory of Pondicherry(Mahe).The institution is being developed as postgraduate institute of oncology sciences and research as per the resolution of 9th Governing body held at MCC. The main objective being establishing a modern cancer hospital, research and training centre of international standard in the treatment and prevention of cancer. MCC is providing a full spectrum of oncological care as an autonomous not-for-profit institution (200+bedded Hospital) funded by the State Government and other sources. Despite this, MCC provides a variety of patient support systems to assist them in getting treatment in time and completing the treatment. As per the clinical data of MCC, 96% of patients are treated free of

cost or through subsidized rates, at MCC, through various finance supporting schemes of Government and through donations from various NGO's, philanthropists etc;- . It has been undertaken by MCC, that no patients will be denied treatment for financial reasons. The control and management of the Centre are vested in the Governing Body consisting of 23 members. The routine activities and functions of the Centre are supervised by an Executive Committee, with the Secretary, Health & Family Welfare Department, being the Chairman of the Committee. All cancer survivors should have follow-up care. Follow-up care for cancer means consulting a Health care provider for regular medical checkups, once you have finished with treatment. These checkups may include blood tests as well as other tests and procedures that may require for your health, or any problems that may occur due to cancer treatment. These visits are also a time to check for physical and emotional problems that may develop, for months or years for prevention.

ORGANISATION

Governing Body (GB): The Governing Body of the Society consists of 23 members.

1	Chairman	Chief Minister of Kerala
2	Vice-Chairman	Minister for Health & FW, Kerala
3	Alternate Vice-Chairman	Minister for Electricity, Kerala
4	Member	Secretary, Department of Finance, Kerala
5	Member	Secretary, Department of Power, Kerala
6	Member	District Medical Officer, Kannur
7	Member	Secretary, Department of Health & FW, Kerala
8	Member	An eminent Medical Scientist
9	Member	Secretary, Department of Science, Technology & Environment
10	Member	One nominee of the Ministry of Health, Government of India
11	Member	Principal, Medical College, Kozhikode
12	Member	Secretary- Planning & Economic Affairs Department, Kerala
13	Member	Director- Rajiv Gandhi Centre for Bio technology, Trivandrum
14	Member	Director of Medical Education, Directorate of Medical Education, Trivandrum
15	Member & Secretary to GB	Director, Malabar Cancer Centre, Thalassery

16	Member	M.L.A. of the Thalassery constituency
17	Member	President, District Panchayat, Kannur District
18	Member	Chairman, Thalassery Municipality, Thalassery
19	Member	A public man from North Malabar region (to be nominated by Government of Kerala)
20	Member	One Head of the department nominated from Malabar Cancer centre, Thalassery by the Government.
21	Member	One nominee of the Charitable Society established for rehabilitation and financial assistance for poor cancer patients
22	Member	Principal/Chief Executive Officer of Medical College, Pariyaram
23	Member	Director, Regional Cancer Centre, Trivandrum

EXECUTIVE COMMITTEE

Executive Committee (EC): The Executive Committee shall be composed of;

1	Secretary, Health & Family Welfare Department	Chairman
2	Secretary, Finance Department	Member
3	Secretary, Planning and Economic Affairs Department	Member
4	Secretary, Power Department	Member
5	MLA of the Constituency in which MCC is situated	Member
6	Director of Medical Education	Member
7	Chairman, Thalassery Municipality	Member
8	Director, Regional Cancer Centre, Trivandrum	Member
9	Director, Cochin Cancer Centre and Research Centre, Kochi	Member
10	Director, Malabar Cancer Centre	Member/Convenor

DEPARTMENT OF CANCER REGISTRY & EPIDEMIOLOGY

Department of Cancer Registry and Epidemiology was established in the year 2010 and started Hospital Based Cancer Registry partially supported by National Cancer Registry Programme (ICMR), Bangalore. The department routinely published the Hospital Based Cancer Registry reports and this is

the 13th report of Hospital Based Cancer Registry. The Hospital Based Cancer registry project was re-named as Hospital Based Cancer Registry in India-NCIDR/ICMR and funded by ICMR, Bengaluru, 01.04.2022 to 31.03.2027.

STAFF [Department of Cancer Registry & Epidemiology]

Sl. No	Name	Designation
1.	Dr. Saina Sunil Kumar	Lecturer [HOD in charge]
2.	Dr. Bindu T	Lecturer in Biostatistics
3.	Dr. Ratheesan K	Lecturer in Biostatistics
4.	Sri. Prachith K S	Coding Clerk
5.	Smt. Sheena E	Data Entry Operator [Outsource]
6.	Smt. Nisha K	Data Entry Operator [Outsource]

PROJECT STAFF

Sl. No	Name	Designation
1.	Nijin P	Social Worker[HBCR]
2.	Rejisha R	Registry Data Entry Operator [HBCR]
3.	Shibin Mathew	Social worker [POCSS]
4.	Akshaj E	Registry Data Entry Operator[POCSS]
5.	Athira M	Data Entry Operator [POCSS]

Currently, the department has the following programmes.

➤ **Hospital based cancer registry in India[Under the network of NCDIR/ ICMR]**

➤ **Population Based Cancer Registry [Under the network of NCDIR/ ICMR]**

The department launched Malabar Population Based Cancer Registry partially supported by NCDIR, Bangalore in 2014 for three districts of Kannur, Kasaragod & Mahe. The department also published four PBCR reports for years 2015, 2016 2017 and 2018. The department expanded the PBCR area to five other neighboring districts of Wayanad, Kozhikode, Malappuram, Thrissur and Palakkad in 2018.

➤ **A study on patterns of care and survival of head and neck, breast and cervical cancers in India under the Hospital Based Cancer Registries of National Cancer Registry Program [Under the network of NCDIR/ICMR]**

Funded project of NCRP/ICMR, Patterns of Care & Survival Studies in Breast, Cervix & Head & Neck cancers started in 2014. The project was renamed as “**A study on Patterns of Care & Survival of Breast, Cervix and Head & Neck Cancers in India**”.

Hospital based cancer registry in India [Under the network of NCDIR/ ICMR]:

Hospital based cancer registries collect information of cancers reported in a given hospital, regardless of where that person with cancer resides. Hospital based registries help in assessing cancer patient care in a given hospital and aid in hospital administration including the individual hospital's cancer control programmes. Hospital registries help in planning and monitoring survival studies and clinical trials. Hospital registries contribute cases to the population based cancer registry in the area. The primary purpose of Hospital Based Cancer Registries is to contribute to patient care by providing readily accessible information on the patients with cancer, the treatment received and its results. The data is also used for clinical research and for epidemiological purposes. Hospital based cancer registries are concerned with recording of information on the cancer patients seen in a particular hospital (Isabel dos Santos Silva et al, 1999). Within the hospital, a registry is often considered to be an integral part of the hospital's cancer Programme or health care delivery system.

In hospital based cancer registry, the data abstraction and entry are done using the hospital files. The core proforma contains the demographic details, diagnostic, treatment and follow up details. The details of the ICMR core proforma are entered using the ICMR software after retrieving case sheets from the MCC Medical Records division. All variables in the core pro forma except age and various dates are directly selected. The selection box contains all the codes along with their descriptions for each variable. Hence, this helps to avoid mistakes beyond the range of values for each variable. The selection box corresponding to the variable topography and morphology contains the third edition of international classification of diseases for oncology (ICD-O-3) and the international classification of diseases (ICD-10).

After abstraction, coding and data entry the data were sent to the coordinating unit of the NCRP of ICMR, Bangalore in an electronic format and the data was subjected to various range, consistency, unlikely combinations, and duplicate checks. Necessary corrections are done based on the error list of the cases sent by the coordinating unit and this report is generated.

NATIONAL CANCER REGISTRY PROGRAMME [INDIAN COUNCIL OF MEDICAL RESEARCH]

The Indian Council of Medical Research initiated a network of cancer registries across the country under the National Cancer Registry Programme (NCRP) in December 1981. This move followed the recognition that there was an urgent need for strengthening the existing cancer registries and organization of new cancer registries in different regions of the country.

The Programme had commenced with the following objectives:

1. To generate reliable data on the magnitude and patterns of cancer – this would be based on morbidity and mortality rates including incidence rates according to gender, age and residence of the patient, anatomical site of cancer and proportion of histological type or microscopic confirmation for each site; pattern of different types of cancer according to relative proportions or ratios in various population sub-groups such as religion, language spoken, educational status; clinical stage of disease when patients come to hospital for treatment and where possible the nature of treatment received and outcome;
2. To undertake epidemiologic studies in the form of case control or cohort studies based on observations of registry data;
3. Provide research base for developing appropriate strategies to aid in National Cancer Control Programme; this would be in the form of planning, monitoring and evaluation of activities under this Programme;
4. Develop human resource in cancer registration and Epidemiology.

SUMMARY OF RESULTS

- During the year 2022, a total of 6059 cancer patients were registered at MCC and among them 3130 (51.7%) were males and 2929 (48.3%) were females.
- Average age at diagnosis was 60.2 years (SD: 14.8) in males and 56.4 years (SD: 14.8) in females.
- Among the cancer cases reported for the year 2022, date of diagnosis was 2022 itself for 4962 (81.9%) cases and the remaining cases had their date of diagnosis was in the previous years.
- Among males Lung cancer (17.0%) was the leading site followed by Stomach cancer (6.1%). The third leading cancer was mouth (6.0%).
- Among females, Breast cancer (29.2%) was the leading site of cancer followed by thyroid (8.6%). The third leading cancer was cervix (5.8%).
- Considering the five year age group, the peak age group was 60-64 years in both males and females.
- Children (0-14 years) constitute 1.6% of all cancers and in children leukaemia was the leading cancer in both genders.
- 4.6% of all cancers were in age group 15-34 years. In this age group thyroid cancer was the leading cancer in both males (13.2%) and females (29.7%).
- 56.0% of all cancers were in age group 35-64 years. In 35-64 age group lung cancer (13.3%) was the leading cancer in males and breast cancer (35.8%) was the leading cancer in females.
- 37.8% of all cancers were in age group 65+ years. In this age group lung cancer (23.3%) was the leading cancer in males and breast cancer (19.4%) was the leading cancer in females.
- The proportion of tobacco related cancer relative to all cancers was 43.4% in males and 12.3% in females.
- The peak age group for tobacco related cancer was 60-64 years in males (20.9%) and 75+ years in females (21.1%).
- Among 6059 registered cases, 88.2% of males and 94.7% of females were microscopically diagnosed.
- Among the microscopically diagnosed cases, histology of primary was available in 86.5% of males and 91.0% of females


- Among 6059 cancer cases, 997(16.5%) of patients received prior treatment only, 887(14.6%) of patients received prior treatment and treatment at MCC and 2477 (40.9%) of patients received treatment only at MCC.
- Among 2477 patients who received treatment only at MCC 1251 (50.5%) were males and 1226(49.5%) were females.
- The system wise leading cancer was digestive organ (63.5% males and 36.5% females) followed by head and neck cancer (76.3% males and 23.7% females).

Patterns of Patient Registration, 2022

Type	Total
Total Registration	7880
Malignant [including multiple primaries]	6059
Non malignant	1821

Table 1: Patterns of Patient Registration

Figure 1: Annual Number of Cancer patients, HBCR (2010-2022)



DISTRICT WISE CANCER REGISTRATION HBCR 2022

Table 2: Districtwise Patients Registration

District	Patients	%
Kannur	2990	49.4%
Kasaragod	1032	17.1%
Kozhikode	915	15.1%
Malappuram	454	7.5%
Wayanad	282	4.6%
Palakkad	128	2.1%
Thrissur	73	1.2%
Ernakulam	18	0.3%
Thiruvananthapuram	14	0.2%
Kottayam	13	0.2%
Kollam	11	0.2%
Alappuzha	8	0.1%
Idukki	7	0.1%
Pathanamthitta	1	0.0%
Other states		
Pondicherry	30	0.5%
Tamilnadu	16	0.3%
Karnataka	50	0.8%
Other states	17	0.3%



**NATIONAL CENTER FOR DISEASE
INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**


(Indian Council of Medical Research)
**Hospital Based Cancer Registry
524 - Malabar Cancer Centre, Kannur**

**Report Based on Year of Registration: 2022
MAGNITUDE OF CANCERS**

During the year 2022, the total number of cancer patients registered in the HBCR was 6059 [Male: 3130, Female: 2929] and the male to female ratio was 1.07:1

Table 3: Number (#) and Proportion (%) according to Sex and Sex Ratio Percent

Males		Females		Total Cases
#	%	#	%	
3130	51.7	2929	48.3	6059



LEADING SITE OF CANCERS

Table 4: Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer- Males

Relative proportion of Ten leading site of cancer – Males

Rank	Sites(ICD 10)	#	%
1	Lung etc. (C33-34)	533	17.0
2	Stomach (C16)	190	6.1
3	Mouth (C03-06)	189	6.0
4	Liver (C22)	185	5.9
5	Rectum (C19-20)	164	5.2
6	NHL (C82-85,C96)	162	5.2
7	Prostate (C61)	138	4.4
8	Larynx (C32)	127	4.1

9	Tongue (C01-02)	125	4.0
10	Colon (C18)	120	3.8
	All Sites	3130	100





Table 5: Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer- Females

Rank	Sites (ICD-10)	#	%
1	Breast (C50)	856	29.2
2	Thyroid (C73)	253	8.6
3	Cervix (C53)	171	5.8
4	Ovary etc. (C56)	171	5.8
5	Corpus Uteri (C54)	170	5.8
6	Rectum (C19-20)	127	4.3
7	Lung etc. (C33-34)	121	4.1
8	Colon (C18)	114	3.9
9	NHL (C82-85,C96)	109	3.7
10	Mouth (C03-06)	84	2.9
	All Sites	2929	100



CANCER SITES BY AGE AND GENDER

Five year age group

- Peak age group : 60-64in males and females
- Mean age at diagnosis : 60.2 years for males and 56.3years for females

Table 6: Five Year Age Distribution

Age in years	Male(N=3130)		Female(N=2929)		Total(6059)	
	#	%	#	%	#	%
00-04	35	1.1	18	0.6	53	0.9
05-09	8	0.3	6	0.2	14	0.2
10-14	17	0.5	12	0.4	29	0.5
15-19	26	0.8	25	0.9	51	0.8
20-24	25	0.8	26	0.9	51	0.8
25-29	23	0.7	31	1.1	54	0.9
30-34	47	1.5	73	2.5	120	2.0
35-39	70	2.2	130	4.4	200	3.3
40-44	133	4.2	231	7.9	364	6.0
45-49	169	5.4	338	11.5	507	8.4
50-54	273	8.7	362	12.4	635	10.5
55-59	329	10.5	368	12.6	697	11.5
60-64	594	19.0	397	13.6	991	16.4
65-69	526	16.8	352	12.0	878	14.5
70-74	488	15.6	293	10.0	781	12.9
75+	367	11.7	267	9.1	634	10.5

Broad age group

□ 50.1% of males and 62.3% females were in the age group 35-64 years


Table 7: Number and Proportion of Patients according to Broad age group

Broad Age Groups	Males(N=3130)		Females(N=2929)		Total(N=6059)	
	#	%	#	%	#	%
00-14	60	1.9	36	1.2	96	1.6
15-34	121	3.9	155	5.3	276	4.6
35-64	1568	50.1	1826	62.3	3394	56.0
65+	1381	44.1	912	31.1	2293	37.8

Table 8 :Number(#) and proportion of leading site of cancer and broad age group

Age	Male				Female			
	Rank	Leading sites	#	%	Rank	Leading sites	#	%
0-14	1	Lymphoid Leukaemia	21	35	1	Lymphoid Leukaemia	8	22.2
	2	Myeloid Leukaemia	9	15	2	Myeloid Leukaemia	5	13.9
	3	Eye	7	11.7	3	Bone	5	13.9
	4	Brain, Nervous system	6	10	4	Thyroid	4	11.1
	5	NHL	5	8.3	5	Conn & Soft Tissue	3	8.3
15-34	1	Thyroid	16	13.2	1	Thyroid	46	29.7
	2	Myeloid Leukaemia	14	11.6	2	Breast	26	16.8
	3	NHL	13	10.7	3	NHL	9	5.8
	4	Bone	12	9.9	4	Myeloid Leukaemia	7	4.5
	5	Lymphoid Leukaemia	11	9.1	5	Bone	7	4.5
35-64	1	Lung	209	13.3	1	Breast	653	35.8
	2	Mouth	107	6.8	2	Thyroid	173	9.5
	3	Stomach	98	6.3	3	Corpus Uteri	123	6.7
	4	Liver	92	5.9	4	Ovary	108	5.9
	5	Rectum	91	5.8	5	Cervix	107	5.9
65+	1	Lung	322	23.3	1	Breast	177	19.4
	2	Prostate	97	7.0	2	Rectum	65	7.1
	3	Liver	92	6.7	3	Cervix Uteri	61	6.7
	4	Stomach	91	6.6	4	Mouth	52	5.7
	5	Mouth	78	5.6	5	Ovary	51	5.6

Five Leading Cancer Sites by broad age group



TOBACCO RELATED CANCERS

Table 9: Number (#) and Proportion (%) of Cancers associated with Tobacco Relative to all sites of Cancer

Males			Females		
All Sites	#	%	All Sites	#	%
3130	1358	43.4	2929	361	12.3

Table 10: Number (#) and Proportion (%) of Tobacco Related Cancers (TRC) relative to all sites of Cancer

Sites of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	6	0.2	7	0.2
Tongue (C01-02)	125	3.9	52	1.8
Mouth (C03-06)	189	6.0	84	2.9
Oropharynx (C10)	105	3.4	6	0.2
Hypopharynx (C12-13)	72	2.3	18	0.6
Pharynx (C14)	-	-	1	0.03
Oesophagus (C15)	110	3.5	46	1.6
Larynx (C32)	127	4.1	12	0.4
Lung (C33-34)	533	17.0	121	4.1
Urinary Bladder (C67)	91	2.9	14	0.5
TRC	1358	43.4	361	12.3
All Sites	3130	100	2929	100

Table 11: Number (#) and Proportion (%) of Specific Sites of Cancers among Tobacco Related Cancers (TRC)

Sites of Cancer	Males		Females	
	#	%	#	%
Lip (C00)	6	0.4	7	1.9
Tongue (C01-02)	125	9.2	52	14.4
Mouth (C03-06)	189	13.9	84	23.3
Oropharynx (C10)	105	7.7	6	1.7
Hypopharynx (C12-13)	72	5.3	18	5.0
Pharynx (C14)	-	-	1	0.3

Oesophagus (C15)	110	8.1	46	12.7
Larynx (C32)	127	9.4	12	3.3
Lung (C33-34)	533	39.2	121	33.5
Urinary Bladder (C67)	91	6.7	14	3.9
TRC	1358	100	361	100

Table 12 :Number (#) and Proportion (%) of Tobacco Related Cancers (TRC) by Five year age group

Age group	Males		Females	
	#	%	#	%
00-14	-	-	-	-
15-19	-	-	1	0.3
20-24	-	-	1	0.3
25-29	3	0.2	1	0.3
30-34	11	0.8	5	1.4
35-39	21	1.5	4	1.1
40-44	41	3.0	14	3.9
45-49	59	4.3	19	5.3
50-54	106	7.8	31	8.6
55-59	140	10.3	38	10.5
60-64	284	20.9	55	15.2
65-69	269	19.8	60	16.6
70-74	235	17.3	56	15.5
75+	189	13.9	76	21.1
All Ages	1358	100	361	100

Peak age group of tobacco related cancer was 60-64 in males and 65-69 in females

METHOD OF DIAGNOSIS

Table 13 : Number (#) and Proportion (%) of Cancers by Method of Diagnosis

Method of Diagnosis	Males (N=3130)		Females (N=2929)		Total (N=6059)	
	#	%	#	%	#	%
Microscopic	2761	88.2	2774	94.7	5535	91.4
X-Ray/ Imaging Techniques	340	10.9	123	4.2	463	7.6
Clinical	8	0.3	9	0.3	17	0.3
Others	21	0.7	23	0.8	44	0.7
Unknown	-	-	-	-	-	-
Total	3130	100	2929	100	6059	100

Table 14: Number (#) and Proportion (%) of Cancers by Different Types of Microscopic Diagnosis

Types of Microscopic Diagnosis	Males (N=2761)		Females (N=2774)		Total (N=5535)	
	#	%	#	%	#	%
Histology of Primary	2389	86.5	2525	91.0	4914	88.8
Histology of Metastasis	115	4.2	83	3.0	198	3.6
Cytology of Primary	70	2.5	54	1.9	124	2.2
Cytology of Metastasis	80	2.9	34	1.2	114	2.1
Blood Film	24	0.9	15	0.5	39	0.7
Bone Marrow	83	3.0	63	2.3	146	2.6

Table 15: Number (#) and Proportion (%) of Cancers by Different Types of Microscopic Diagnosis (Includes Non-Microscopic Cases)

Types of Microscopic Diagnosis	Males (N=3130)		Females (N=2929)		Total (N=6059)	
	#	%	#	%	#	%
Histology of Primary	2389	76.3	2525	86.2	4914	81.1
Histology of Metastasis	115	3.7	83	2.8	198	3.3
Cytology of Primary	70	2.2	54	1.8	124	2.0
Cytology of Metastasis	80	2.6	34	1.2	114	1.9
Blood Film	24	0.8	15	0.5	39	0.6
Bone Marrow	83	2.7	63	2.2	146	2.4
Non Microscopic	369	11.8	155	5.3	524	8.6

CLINICAL EXTENT OF DISEASE

Table 16: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (Treatment only at RI)

Clinical Extent	Males(N=1251)		Females(N=1226)		Total(N=2477)	
	#	%	#	%	#	%
Localised	263	21.0	462	37.7	725	29.3
Regional	473	37.8	402	32.8	875	35.3
Distant	325	26.0	236	19.2	561	22.6
Others	190	15.2	126	10.3	316	12.8

Table 17: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (Prior Treatment Only)

Clinical Extent	Males (N=518)		Females (N=479)		Total (N=997)	
	#	%	#	%	#	%
Localised	11	2.1	12	2.5	23	2.3
Regional	10	1.9	8	1.7	18	1.8
Distant	28	5.4	15	3.1	43	4.3
Others	469	90.5	444	92.7	913	91.6

Table 18: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (Prior & Treatment at MCC)

Clinical Extent	Males (N=338)		Females (N=549)		Total (N=887)	
	#	%	#	%	#	%
Localised	7	2.1	27	4.9	34	3.8
Regional	17	5.0	34	6.2	51	5.7
Distant	12	3.6	15	2.7	27	3.0
Others	302	89.3	473	86.2	775	87.4

Table 19: Number (#) and Proportion (%) of Cancers by Clinical Extent of Disease (No Treatment)

Clinical Extent	Males (N=1023)		Females (N=675)		Total (N=1698)	
	#	%	#	%	#	%
Localised	118	11.5	106	15.7	224	13.2
Regional	238	23.3	168	24.9	406	23.9
Distant	480	46.9	278	41.2	758	44.6
Others	187	18.3	123	18.2	310	18.3
Unknown	-	-	-	-	-	-

CANCER DIRECTED TREATMENT

Prior Treatment Only:

Patients who received partial or complete cancer directed treatment before registration at MCC and not received any further treatment at MCC.

Prior and Treatment at MCC:

Patients who received some cancer directed treatment prior to registration at MCC and also at MCC.

Treatment Only at MCC:

Patients reporting for the first time at MCC with or without a confirmed diagnosis of malignancy and receiving cancer directed treatment at MCC

No Treatment:

Patients who have not received any cancer directed treatment before registration at MCC and not received any further treatment at MCC.

Table 20: Number (#) and Relative Proportion (%) of Patients by Broad Treatment Group

Treatment	Males (N=3130)		Females (N=2929)		Total (N=6059)	
	#	%	#	%	#	%
Prior treatment Only	518	16.5	479	16.4	997	16.5
Prior treatment & treatment at MCC	338	10.8	549	18.7	887	14.6
Treatment Only at MCC	1251	39.9	1226	41.9	2477	40.9
No treatment	1023	32.7	675	23.0	1698	28.0

Table 21: Number (#) and Relative Proportion (%) of Patients according to type of treatment given (Treatment Only at MCC)

	Males (N=1251)		Females (N=1226)		Total (N=2477)	
	#	%	#	%	#	%
Surgery	136	10.9	151	12.3	287	11.6
Radiotherapy	390	31.2	163	13.3	553	22.3
Chemotherapy	245	19.6	180	14.7	425	17.2
S + R	105	8.4	70	5.7	175	7.1
S + C	61	4.9	96	7.8	157	6.3
R + C	220	17.6	113	9.2	333	13.4
S + R + C	48	3.8	92	7.5	140	5.7
Others	46	3.7	361	29.4	407	16.4

Table 22: Number (#) and Relative Proportion (%) of Cancer Patients according to Any Specific Treatment relative to all Treatment Procedures (Treatment Only at RI)

Treatments	Males (N=1765)		Females (N=2534)		Total (N=4299)	
	#	%	#	%	#	%
Any Surgery	352	19.9	708	27.9	1060	24.7
Any Radiotherapy	785	44.5	699	27.6	1484	34.5
Any Chemotherapy	582	32.9	766	30.2	1348	31.4
Any Hormone Therapy	43	2.4	360	14.2	403	9.4
Others	3	0.2	1	0.0	4	0.1

Table 23: Number(#) and Proportion(%) of Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated)

Treatment Status	Males (N=2274)		Females (N=1901)		Total (N=4175)	
	#	%	#	%	#	%
Received	1251	55.0	1226	64.5	2477	59.3
Not Received	721	31.7	441	23.2	1162	27.8
Not Accepted	250	11.0	152	8.0	402	9.6
Incomplete	52	2.3	82	4.3	134	3.2

Intention to Treat:

Table 24: Number (#) and Relative Proportion (%) of Cancers by intent to treat [Excluding Previously treated]

Intention to treat	Male (N=1251)		Female (N=1226)		Total (N=2477)	
	#	%	#	%	#	%
Radical	729	58.3	918	74.9	1647	66.5
Palliative	521	41.6	304	24.8	825	33.3
Pain Relief Only	-	-	2	0.2	2	0.08
Symptomatic	1	0.1	2	0.2	3	0.12

CHILDHOOD CANCER

Table 25: Number (#) and Proportion (%) of Cancers in Childhood relative to all Cancers

Boys			Girls		
All Cancers	#	%	All Cancers	#	%
3130	61	1.9	2929	36	1.2

Table 26: Number (#) and Proportion(%) of Childhood Cancers by Five-year Age Group

Age Groups	Boys		Girls		Total	
	#	%	#	%	#	%
00-04	36	59.0	18	50.0	54	55.7
05-09	8	13.1	6	16.7	14	14.4
10-14	17	27.9	12	33.3	29	29.9
All Childhood Cancers	61	100	36	100	97	100

Table 27: Number(#) and Relative Proportion(%) of Broad Types of Cancers in-Childhood (0-14 years)

Broad Type of Cancers in Childhood	Boys		Girls	
	#	%	#	%
Leukaemias	31	50.8	13	36.1
Lymphomas & Reticuloendothelial Neop	5	8.2	1	2.8
CNS & Misc Intracranial & Intraspinial Neop	6	9.8	1	2.8
Sympathetic Nervous System Tumors	2	3.3	4	11.1
Retinoblastoma	7	11.5	3	8.3
Renal Tumors	4	6.6	-	-
Hepatic Tumours	1	1.6	1	2.8
Malignant Bone Tumours	1	1.6	5	13.9
Soft Tissue (S-T) Sarcomas(S)	1	1.6	1	2.8
Germ-Cell Trophoblastic & Oth. Gondal Neop.	-	-	-	-
Carcinoma & Oth Malignant Epithelial Neop.	-	-	-	-
Other & Unsp Malignant Neoplasms	-	-	1	2.8
Others (Not Classified)	3	4.3	6	16.7
All Types	61	100	36	100

Table 28 :Number (#) and Relative Proportion (%) of Specific Types of Cancers in Childhood (0-14 years)

Specific Types of Cancers in Childhood	Boys		Girls	
	#	%	#	%
LEUKAEMIAS	31	50.8	13	36.1
Lymphoid Leukaemias	22	36.1	10	27.8
Acute non-lymphocytic Leukaemias	8	13.1	2	5.6
Unsp. Leukaemias	1	1.6	-	-
LYMPHOMAS & RETICULOENDOTHELIAL NEOP.	5	8.2	1	2.8
Hodgkin"s Disease	2	3.3	-	-
Non-Hodgkin"s Disease	1	1.6	-	-
Burkitt"s Lymphoma	1	1.6		
Misc Lymphoreticularneop.	1	1.6	1	2.8
C.N.S & MISC. INTRACRANIAL & INTRASPINAL NEOP.	6	9.8	1	2.8
Ependymoma	1	1.6	-	-
Astrocytoma	1	1.6	-	-
Primitive Neuroectodermal Tumours	2	3.3	1	2.8
Other Gliomas	2	3.3	-	-
SYMPATHETIC NERVOUS SYSTEM TUMOURS	2	3.3	4	11.1
Neuroblastoma and Ganglioneuroblastoma	2	3.3	4	11.1
RETINOBLASTOMA	7	11.5	3	8.3

RENAL TUMOURS	4	6.6	-	-
Wilms's Tumour, Rhabdoid and clear cell Sarcoma	3	4.9	-	-
Renal Carcinoma	1	1.6		
HEPATIC TUMOURS	1	1.6	1	2.8
Hepatoblatoma	1	1.6		
Hepatic Carcinoma	*	-	1	2.8
MALIGNANT BONE TUMOURS	1	1.6	5	13.9
Osteosarcoma	-	-	4	11.1
Ewing's Sarcoma	1	1.6	1	2.8
SOFT-TISSUE(S-T) SARCOMAS(S)	1	1.6	1	2.8
Rhabdomyosarcoma and embryonal Sarcoma			1	2.8
Fibros. neurofibros. and othFibromatousneop	1	1.6	-	-
OTHER & UNSP. MALIGNANT NEOPLASMS			1	2.8
Other unsp. Malignant Tumours			1	2.8
OTHERS (Not Classified)	3	4.9	6	16.7
ALL TYPES	61	100	36	100

DEMOGRAPHIC DETAILS

TABLE 29: NUMBER (#) AND RELATIVE PROPORTION OF CANCERS BY EDUCATION

Education	Males (N=3130)		Females (N=2929)		Total (N=6059)	
	#	%	#	%	#	%
Middle	1145	36.6	1043	35.6	2188	36.1
Primary	631	20.2	524	17.9	1155	19.1
Secondary	499	15.9	441	15.1	940	15.5
Literate	339	10.8	329	11.2	668	11.0
Illiterate	280	8.9	326	11.1	606	10.0
Others	225	7.2	259	8.8	484	7.9
Unknown	11	0.4	7	0.2	18	0.3

Table 30: Number (#) and Relative Proportion of Cancers by Marital Status

Marital Status	Males (N=3130)		Females (N=2929)		Total (N=6059)	
	#	%	#	%	#	%
Unmarried	176	5.6	152	5.2	328	5.4
Married	2928	93.5	2461	84.0	5389	88.9
Widowed	18	0.6	286	9.8	304	5.0
Divorced	8	0.3	28	1.0	36	0.6
Seperated	-	-	1	0.0	1	0.02
Unknown	-	-	1	0.0	1	0.02

**DETAILED
INFORMATION
NCRP-ICMR
DIAGNOSTIC,
CLINICAL AND
DEMOGRAPHIC**

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2022

TABLE 1(a): Number of cancers by site (ICD-10) and Five Year Age Group - Males

As on: 23/05/2024

ICD 10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unk	Total	%
C00	Lip	-	-	-	-	-	-	-	-	-	1	-	1	2	1	-	1	-	6	0.2
C01-02	Tongue	-	-	-	-	-	2	6	7	8	18	18	17	17	13	10	9	-	125	4.0
C03-06	Mouth	-	-	-	-	-	-	4	10	13	12	20	23	29	27	25	26	-	189	6.0
C07-08	Salivary Gland	-	-	-	-	-	1	-	1	1	3	2	1	5	3	1	2	-	20	0.6
C09	Tonsil	-	-	-	-	1	-	-	-	-	-	-	-	-	-	1	1	-	3	0.1
C10	Oth. Oropharynx	-	-	-	-	-	-	-	1	4	4	17	12	26	15	15	11	-	105	3.4
C11	Nasopharynx	-	-	-	-	1	-	-	-	-	3	1	1	-	-	1	1	-	8	0.3
C12-13	Hypopharynx	-	-	-	-	-	-	-	1	3	-	5	6	17	15	12	13	-	72	2.3
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	-	-	-	-	-	1	-	3	7	13	22	33	19	12	-	110	3.5
C16	Stomach	-	-	-	-	-	-	1	2	8	12	26	21	29	36	33	22	-	190	6.1
C17	Small Intestine	-	-	-	-	-	-	-	1	3	-	-	2	2	-	2	1	-	11	0.4
C18	Colon	-	-	-	-	-	1	1	4	4	13	12	13	24	19	16	13	-	120	3.8
C19-20	Rectum	-	-	-	1	-	1	1	2	9	7	18	19	36	27	29	14	-	164	5.2
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	2	1	-	1	-	1	-	5	0.2
C22	Liver	1	-	-	-	-	-	-	1	5	5	9	27	45	43	31	18	-	185	5.9
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	-	1	1	6	2	7	2	11	3	-	33	1.1
C25	Pancreas	-	-	-	-	-	2	1	1	2	3	12	3	9	7	5	7	-	52	1.7
C30-31	Nose, Sinuses etc.	-	-	-	1	-	-	-	-	-	-	-	3	1	2	-	1	-	8	0.3
C32	Larynx	-	-	-	-	-	-	-	1	2	4	10	15	33	22	20	20	-	127	4.1
C33-34	Lung etc.	-	-	-	-	-	1	1	-	7	10	26	43	123	131	116	75	-	533	17.0
C37-38	Other Thoracic Organs	-	-	-	-	2	-	-	3	-	1	1	-	2	2	-	-	-	11	0.4
C40-41	Bone	-	-	1	7	2	1	2	2	3	2	-	2	1	1	1	1	-	26	0.8
C43	Melanoma of Skin	-	-	-	-	1	-	-	1	1	1	-	1	3	4	1	1	-	14	0.4
C44	Other Skin	-	-	-	-	-	1	1	2	1	3	-	3	10	5	5	11	-	42	1.3
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	-	-	1	3	1	1	3	3	7	6	3	5	7	2	2	2	-	46	1.5
C50	Breast	-	-	-	-	-	-	-	-	-	-	-	-	2	1	1	1	-	5	0.2
C60	Penis	-	-	-	-	-	-	-	-	1	-	2	-	2	1	1	-	-	7	0.2
C61	Prostate	-	-	-	-	-	-	-	-	-	-	5	16	20	27	35	35	-	138	4.4
C62	Testis	-	-	-	-	-	-	1	-	-	2	1	-	-	-	-	-	-	4	0.1
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	0.0
C64	Kidney etc.	3	-	1	-	-	-	1	-	7	-	6	9	9	10	6	4	-	56	1.8
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	-	2	0.1
C66	Ureter	-	-	-	-	-	-	-	-	2	-	-	1	2	-	-	-	-	5	0.2
C67	Bladder	-	-	-	-	-	-	-	-	4	7	3	10	15	12	18	22	-	91	2.9
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	7	-	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	8	0.3
C70-72	Brain, Nervous System	2	2	2	2	1	1	5	3	5	7	11	4	7	2	5	1	-	60	1.9
C73	Thyroid	-	-	1	3	4	3	6	4	4	11	6	6	12	8	6	3	-	77	2.5
C74	Adrenal Gland	1	-	-	-	-	-	-	-	-	-	-	-	-	1	-	1	-	3	0.1
C81	Hodgkins Disease	-	1	1	2	2	-	-	2	1	2	2	3	-	1	-	-	-	17	0.5
C82-85,C96	NHL	1	1	3	-	2	4	7	7	14	12	18	13	25	27	23	5	-	162	5.2
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	-	-	1	0.0
C90	Multiple Myeloma	-	-	-	-	-	-	-	2	3	6	8	17	22	9	9	7	-	83	2.7
C91	Lymphoid Leuk.	13	3	5	4	4	2	1	2	2	4	3	3	6	4	4	3	-	63	2.0
C92-94	Myeloid Leukaemia	6	1	2	3	4	2	5	5	7	4	9	9	6	7	3	4	-	77	2.5
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	-	-	-	-	-	-	1	-	2	4	3	15	5	20	14	-	65	2.1
	All Sites	35	8	17	26	25	23	47	70	133	169	273	329	594	526	488	367	-	3130	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 1(b): Number of cancers by site (ICD-10) and Five Year Age Group - Females

As on: 23/05/2024

ICD 10	Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unk	Total	%
C00	Lip	-	-	-	-	-	-	-	-	1	-	-	-	-	-	2	4	-	7	0.2
C01-02	Tongue	-	-	-	-	-	-	2	1	1	3	6	2	8	11	6	12	-	52	1.8
C03-06	Mouth	-	-	-	-	-	-	3	-	3	6	4	6	10	13	8	31	-	84	2.9
C07-08	Salivary Gland	-	-	-	1	-	-	-	1	-	3	2	-	3	-	1	1	-	12	0.4
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	-	2	-	1	2	1	-	-	6	0.2
C11	Nasopharynx	-	-	-	-	-	-	-	1	-	4	1	1	-	-	-	-	-	7	0.2
C12-13	Hypopharynx	-	-	-	-	-	-	-	-	2	1	-	3	3	2	3	4	-	18	0.6
C14	Pharynx Unspecified	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	-	1	0.0
C15	Oesophagus	-	-	-	-	-	-	-	-	-	1	6	3	7	11	8	10	-	46	1.6
C16	Stomach	-	-	-	-	-	1	1	5	1	6	8	10	12	8	9	9	-	70	2.4
C17	Small Intestine	-	-	-	-	-	-	-	-	1	3	2	2	2	1	-	3	-	14	0.5
C18	Colon	-	-	-	-	-	1	4	3	8	11	12	14	23	13	14	11	-	114	3.9
C19-20	Rectum	-	-	-	-	-	-	1	1	7	10	10	18	15	23	21	21	-	127	4.3
C21	Anus & Anal Canal	-	-	-	-	-	-	-	-	-	-	-	-	2	-	1	2	-	5	0.2
C22	Liver	-	-	1	-	1	-	1	1	2	2	3	5	11	9	12	13	-	61	2.1
C23-24	Gallbladder etc.	-	-	-	-	-	-	-	-	-	4	2	4	4	1	9	2	-	26	0.9
C25	Pancreas	-	-	1	-	-	-	-	-	3	2	7	4	5	6	3	7	-	38	1.3
C30-31	Nose, Sinuses etc.	-	-	-	-	-	-	-	1	-	1	2	-	1	-	2	-	-	7	0.2
C32	Larynx	-	-	-	-	-	-	-	1	1	-	2	2	1	1	2	2	-	12	0.4
C33-34	Lung etc.	-	-	-	-	1	-	-	2	6	8	11	19	24	15	20	15	-	121	4.1
C37-38	Other Thoracic Organs	-	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	-	2	0.1
C40-41	Bone	1	1	3	5	-	-	2	1	-	-	-	2	1	1	-	-	-	17	0.6
C43	Melanoma of Skin	-	-	-	-	-	-	1	-	2	-	-	1	-	5	1	2	-	12	0.4
C44	Other Skin	-	-	-	-	-	-	1	1	1	3	2	4	3	2	5	7	-	29	1.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	1	-	1	-	2	3	1	2	6	3	3	3	4	2	2	-	35	1.2
C50	Breast	-	-	-	-	1	5	20	50	98	144	136	117	108	90	56	31	-	856	29.2
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	2	-	-	-	-	-	2	0.1
C52	Vagina	-	-	-	-	-	-	-	-	-	1	-	1	1	-	1	4	-	8	0.3
C53	Cervix Uteri	-	-	-	-	-	2	1	3	6	17	30	29	22	19	23	19	-	171	5.8
C54	Corpus Uteri	-	-	-	1	-	-	1	2	7	8	32	35	39	27	11	7	-	170	5.8
C55	Uterus Unspecified	-	-	-	-	1	-	-	1	1	2	2	1	1	1	-	-	-	10	0.3
C56	Ovary etc.	-	1	-	3	-	5	3	5	18	20	23	24	18	19	19	13	-	171	5.8
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	1	-	1	-	-	-	-	2	0.1
C58	Placenta	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	-	1	0.0
C64	Kidney etc.	-	-	-	-	-	-	-	1	1	2	2	3	3	3	-	1	-	16	0.5
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	-	-	-	1	-	-	-	-	-	-	-	3	1	3	4	2	-	14	0.5
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	3	-	-	-	-	-	-	1	-	-	-	-	-	-	-	-	-	4	0.1
C70-72	Brain, Nervous System	-	-	1	-	-	1	1	1	2	4	3	6	4	3	3	2	-	31	1.1
C73	Thyroid	-	-	4	5	12	8	21	27	37	41	28	17	23	15	10	5	-	253	8.6
C74	Adrenal Gland	1	-	-	-	-	1	-	-	-	-	-	-	-	1	-	-	-	3	0.1
C81	Hodgkins Disease	-	-	-	-	1	2	2	-	1	-	-	2	-	-	-	1	-	9	0.3
C82-85,C96	NHL	-	1	-	2	4	1	2	9	10	11	10	10	19	15	10	5	-	109	3.7
C88	Malig Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	-	-	2	-	3	5	3	11	9	9	-	42	1.4
C91	Lymphoid Leuk.	7	1	-	3	2	-	-	4	1	3	-	2	3	2	3	4	-	35	1.2
C92-94	Myeloid Leukaemia	2	1	2	3	3	-	1	5	4	7	5	6	7	6	3	2	-	57	1.9
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	2	-	-	-	-	1	1	1	2	4	2	1	5	6	9	8	-	42	1.4
	All Sites	18	6	12	25	26	31	73	130	231	338	362	368	397	352	293	267	-	2929	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 2(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis - Males

As on: 23/05/2024

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C01-02	Tongue	123	98.4	-	-	1	0.8	1	0.8	-	-	125	100.0
C03-06	Mouth	181	95.8	1	0.5	4	2.1	3	1.6	-	-	189	100.0
C07-08	Salivary Gland	20	100.0	-	-	-	-	-	-	-	-	20	100.0
C09	Tonsil	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	104	99.0	-	-	-	-	1	1.0	-	-	105	100.0
C11	Nasopharynx	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C12-13	Hypopharynx	71	98.6	1	1.4	-	-	-	-	-	-	72	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	103	93.6	7	6.4	-	-	-	-	-	-	110	100.0
C16	Stomach	180	94.7	8	4.2	-	-	2	1.1	-	-	190	100.0
C17	Small Intestine	11	100.0	-	-	-	-	-	-	-	-	11	100.0
C18	Colon	104	86.7	14	11.7	-	-	2	1.7	-	-	120	100.0
C19-20	Rectum	160	97.6	1	0.6	-	-	3	1.8	-	-	164	100.0
C21	Anus & Anal Canal	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	51	27.6	134	72.4	-	-	-	-	-	-	185	100.0
C23-24	Gallbladder etc.	22	66.7	10	30.3	-	-	1	3.0	-	-	33	100.0
C25	Pancreas	37	71.2	15	28.8	-	-	-	-	-	-	52	100.0
C30-31	Nose, Sinuses etc.	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	119	93.7	4	3.1	1	0.8	3	2.4	-	-	127	100.0
C33-34	Lung etc.	436	81.8	95	17.8	1	0.2	1	0.2	-	-	533	100.0
C37-38	Other Thoracic Organs	11	100.0	-	-	-	-	-	-	-	-	11	100.0
C40-41	Bone	24	92.3	2	7.7	-	-	-	-	-	-	26	100.0
C43	Melanoma of Skin	14	100.0	-	-	-	-	-	-	-	-	14	100.0
C44	Other Skin	42	100.0	-	-	-	-	-	-	-	-	42	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	46	100.0	-	-	-	-	-	-	-	-	46	100.0
C50	Breast	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	7	100.0	-	-	-	-	-	-	-	-	7	100.0
C61	Prostate	131	94.9	5	3.6	-	-	2	1.4	-	-	138	100.0
C62	Testis	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	46	82.1	10	17.9	-	-	-	-	-	-	56	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C67	Bladder	87	95.6	4	4.4	-	-	-	-	-	-	91	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	7	87.5	1	12.5	-	-	-	-	-	-	8	100.0
C70-72	Brain, Nervous System	52	86.7	8	13.3	-	-	-	-	-	-	60	100.0
C73	Thyroid	76	98.7	-	-	1	1.3	-	-	-	-	77	100.0
C74	Adrenal Gland	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	17	100.0	-	-	-	-	-	-	-	-	17	100.0
C82-85,C96	NHL	161	99.4	1	0.6	-	-	-	-	-	-	162	100.0
C88	Malig Imn.Prol D	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	83	100.0	-	-	-	-	-	-	-	-	83	100.0
C91	Lymphoid Leuk.	63	100.0	-	-	-	-	-	-	-	-	63	100.0
C92-94	Myeloid Leukaemia	77	100.0	-	-	-	-	-	-	-	-	77	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	45	69.2	18	27.7	-	-	2	3.1	-	-	65	100.0
	All Sites	2761	88.2	340	10.9	8	0.3	21	0.7	-	-	3130	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur



Report Based on Year of Registration : 2022

TABLE 2(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis - Females

As on: 23/05/2024

ICD 10	Site Name	Microscopic		X-Ray / Imaging		Clinical		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	85.7	-	-	1	14.3	-	-	-	-	7	100.0
C01-02	Tongue	51	98.1	-	-	1	1.9	-	-	-	-	52	100.0
C03-06	Mouth	78	92.9	1	1.2	4	4.8	1	1.2	-	-	84	100.0
C07-08	Salivary Gland	12	100.0	-	-	-	-	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C11	Nasopharynx	7	100.0	-	-	-	-	-	-	-	-	7	100.0
C12-13	Hypopharynx	17	94.4	-	-	-	-	1	5.6	-	-	18	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	43	93.5	2	4.3	-	-	1	2.2	-	-	46	100.0
C16	Stomach	67	95.7	3	4.3	-	-	-	-	-	-	70	100.0
C17	Small Intestine	13	92.9	1	7.1	-	-	-	-	-	-	14	100.0
C18	Colon	105	92.1	9	7.9	-	-	-	-	-	-	114	100.0
C19-20	Rectum	122	96.1	4	3.1	-	-	1	0.8	-	-	127	100.0
C21	Anus & Anal Canal	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	25	41.0	35	57.4	-	-	1	1.6	-	-	61	100.0
C23-24	Gallbladder etc.	21	80.8	5	19.2	-	-	-	-	-	-	26	100.0
C25	Pancreas	28	73.7	10	26.3	-	-	-	-	-	-	38	100.0
C30-31	Nose, Sinuses etc.	7	100.0	-	-	-	-	-	-	-	-	7	100.0
C32	Larynx	11	91.7	-	-	-	-	1	8.3	-	-	12	100.0
C33-34	Lung etc.	109	90.1	11	9.1	-	-	1	0.8	-	-	121	100.0
C37-38	Other Thoracic Organs	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	17	100.0	-	-	-	-	-	-	-	-	17	100.0
C43	Melanoma of Skin	12	100.0	-	-	-	-	-	-	-	-	12	100.0
C44	Other Skin	29	100.0	-	-	-	-	-	-	-	-	29	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	35	100.0	-	-	-	-	-	-	-	-	35	100.0
C50	Breast	846	98.8	5	0.6	2	0.2	3	0.4	-	-	856	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C53	Cervix Uteri	162	94.7	6	3.5	-	-	3	1.8	-	-	171	100.0
C54	Corpus Uteri	169	99.4	1	0.6	-	-	-	-	-	-	170	100.0
C55	Uterus Unspecified	10	100.0	-	-	-	-	-	-	-	-	10	100.0
C56	Ovary etc.	148	86.5	14	8.2	1	0.6	8	4.7	-	-	171	100.0
C57	Other Female Genital	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	15	93.8	1	6.2	-	-	-	-	-	-	16	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	13	92.9	-	-	-	-	1	7.1	-	-	14	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C70-72	Brain, Nervous System	28	90.3	3	9.7	-	-	-	-	-	-	31	100.0
C73	Thyroid	253	100.0	-	-	-	-	-	-	-	-	253	100.0
C74	Adrenal Gland	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C82-85,C96	NHL	109	100.0	-	-	-	-	-	-	-	-	109	100.0
C88	Malign. Prol. D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	41	97.6	-	-	-	-	1	2.4	-	-	42	100.0
C91	Lymphoid Leuk.	35	100.0	-	-	-	-	-	-	-	-	35	100.0
C92-94	Myeloid Leukaemia	57	100.0	-	-	-	-	-	-	-	-	57	100.0
C95	Leukaemia Uns.	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns.	30	71.4	12	28.6	-	-	-	-	-	-	42	100.0
	All Sites	2774	94.7	123	4.2	9	0.3	23	0.8	-	-	2929	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 3(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis - Males

As on: 23/05/2024

ICD 10	Site	Histology of Primary		Histology of Secondary		Cytology of Primary		Cytology of Metastasis		Blood Film		Bone Marrow		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C01-02	Tongue	117	95.1	-	-	2	1.6	4	3.3	-	-	-	-	123	100.0
C03-06	Mouth	177	97.8	1	0.6	2	1.1	1	0.6	-	-	-	-	181	100.0
C07-08	Salivary Gland	15	75.0	-	-	5	25.0	-	-	-	-	-	-	20	100.0
C09	Tonsil	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	95	91.3	-	-	2	1.9	7	6.7	-	-	-	-	104	100.0
C11	Nasopharynx	6	75.0	1	12.5	-	-	1	12.5	-	-	-	-	8	100.0
C12-13	Hypopharynx	61	85.9	-	-	1	1.4	9	12.7	-	-	-	-	71	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	102	99.0	1	1.0	-	-	-	-	-	-	-	-	103	100.0
C16	Stomach	174	96.7	4	2.2	1	0.6	1	0.6	-	-	-	-	180	100.0
C17	Small Intestine	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C18	Colon	96	92.3	8	7.7	-	-	-	-	-	-	-	-	104	100.0
C19-20	Rectum	158	98.8	1	0.6	-	-	1	0.6	-	-	-	-	160	100.0
C21	Anus & Anal Canal	5	100.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	32	62.7	17	33.3	1	2.0	1	2.0	-	-	-	-	51	100.0
C23-24	Gallbladder etc.	16	72.7	4	18.2	-	-	2	9.1	-	-	-	-	22	100.0
C25	Pancreas	29	78.4	2	5.4	4	10.8	2	5.4	-	-	-	-	37	100.0
C30-31	Nose, Sinuses etc.	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	107	89.9	4	3.4	3	2.5	5	4.2	-	-	-	-	119	100.0
C33-34	Lung etc.	335	76.8	40	9.2	30	6.9	31	7.1	-	-	-	-	436	100.0
C37-38	Other Thoracic Organs	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C40-41	Bone	24	100.0	-	-	-	-	-	-	-	-	-	-	24	100.0
C43	Melanoma of Skin	13	92.9	-	-	1	7.1	-	-	-	-	-	-	14	100.0
C44	Other Skin	41	97.6	-	-	1	2.4	-	-	-	-	-	-	42	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	46	100.0	-	-	-	-	-	-	-	-	-	-	46	100.0
C50	Breast	5	100.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	6	85.7	1	14.3	-	-	-	-	-	-	-	-	7	100.0
C61	Prostate	126	96.2	5	3.8	-	-	-	-	-	-	-	-	131	100.0
C62	Testis	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	44	95.7	2	4.3	-	-	-	-	-	-	-	-	46	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	4	80.0	-	-	-	-	1	20.0	-	-	-	-	5	100.0
C67	Bladder	85	97.7	-	-	2	2.3	-	-	-	-	-	-	87	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	7	100.0	-	-	-	-	-	-	-	-	-	-	7	100.0
C70-72	Brain, Nervous System	52	100.0	-	-	-	-	-	-	-	-	-	-	52	100.0
C73	Thyroid	66	86.8	1	1.3	9	11.8	-	-	-	-	-	-	76	100.0
C74	Adrenal Gland	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	17	100.0	-	-	-	-	-	-	-	-	-	-	17	100.0
C82-85,C96	NHL	138	85.7	-	-	4	2.5	-	-	9	5.6	10	6.2	161	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	1	100.0	1	100.0
C90	Multiple Myeloma	48	57.8	-	-	1	1.2	-	-	-	-	34	41.0	83	100.0
C91	Lymphoid Leuk.	38	60.3	-	-	-	-	-	-	9	14.3	16	25.4	63	100.0
C92-94	Myeloid Leukaemia	49	63.6	-	-	-	-	-	-	6	7.8	22	28.6	77	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	7	15.6	23	51.1	1	2.2	14	31.1	-	-	-	-	45	100.0
	All Sites	2389	86.5	115	4.2	70	2.5	80	2.9	24	0.9	83	3.0	2761	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2022

TABLE 3(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis - Females

As on: 23/05/2024

ICD 10	Site	Histology of Primary		Histology of Secondary		Cytology of Primary		Cytology of Metastasis		Blood Film		Bone Marrow		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C01-02	Tongue	50	98.0	-	-	-	-	1	2.0	-	-	-	-	51	100.0
C03-06	Mouth	75	96.2	1	1.3	1	1.3	1	1.3	-	-	-	-	78	100.0
C07-08	Salivary Gland	12	100.0	-	-	-	-	-	-	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C11	Nasopharynx	6	85.7	1	14.3	-	-	-	-	-	-	-	-	7	100.0
C12-13	Hypopharynx	15	88.2	-	-	-	-	2	11.8	-	-	-	-	17	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	42	97.7	1	2.3	-	-	-	-	-	-	-	-	43	100.0
C16	Stomach	64	95.5	3	4.5	-	-	-	-	-	-	-	-	67	100.0
C17	Small Intestine	12	92.3	1	7.7	-	-	-	-	-	-	-	-	13	100.0
C18	Colon	98	93.3	4	3.8	1	1.0	2	1.9	-	-	-	-	105	100.0
C19-20	Rectum	117	95.9	4	3.3	-	-	1	0.8	-	-	-	-	122	100.0
C21	Anus & Anal Canal	5	100.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	13	52.0	11	44.0	1	4.0	-	-	-	-	-	-	25	100.0
C23-24	Gallbladder etc.	16	76.2	5	23.8	-	-	-	-	-	-	-	-	21	100.0
C25	Pancreas	20	71.4	5	17.9	2	7.1	1	3.6	-	-	-	-	28	100.0
C30-31	Nose, Sinuses etc.	7	100.0	-	-	-	-	-	-	-	-	-	-	7	100.0
C32	Larynx	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C33-34	Lung etc.	81	74.3	12	11.0	6	5.5	10	9.2	-	-	-	-	109	100.0
C37-38	Other Thoracic Organs	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	17	100.0	-	-	-	-	-	-	-	-	-	-	17	100.0
C43	Melanoma of Skin	12	100.0	-	-	-	-	-	-	-	-	-	-	12	100.0
C44	Other Skin	28	96.6	-	-	1	3.4	-	-	-	-	-	-	29	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	35	100.0	-	-	-	-	-	-	-	-	-	-	35	100.0
C50	Breast	824	97.4	6	0.7	15	1.8	1	0.1	-	-	-	-	846	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	8	100.0	-	-	-	-	-	-	-	-	-	-	8	100.0
C53	Cervix Uteri	161	99.4	1	0.6	-	-	-	-	-	-	-	-	162	100.0
C54	Corpus Uteri	166	98.2	2	1.2	1	0.6	-	-	-	-	-	-	169	100.0
C55	Uterus Unspecified	9	90.0	1	10.0	-	-	-	-	-	-	-	-	10	100.0
C56	Ovary etc.	127	85.8	5	3.4	7	4.7	9	6.1	-	-	-	-	148	100.0
C57	Other Female Genital	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	15	100.0	-	-	-	-	-	-	-	-	-	-	15	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	13	100.0	-	-	-	-	-	-	-	-	-	-	13	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C70-72	Brain, Nervous System	28	100.0	-	-	-	-	-	-	-	-	-	-	28	100.0
C73	Thyroid	236	93.3	1	0.4	16	6.3	-	-	-	-	-	-	253	100.0
C74	Adrenal Gland	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	9	100.0	-	-	-	-	-	-	-	-	-	-	9	100.0
C82-85,C96	NHL	92	84.4	-	-	2	1.8	-	-	3	2.8	12	11.0	109	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	17	41.5	2	4.9	-	-	-	-	-	-	22	53.7	41	100.0
C91	Lymphoid Leuk.	22	62.9	-	-	-	-	-	-	2	5.7	11	31.4	35	100.0
C92-94	Myeloid Leukaemia	29	50.9	-	-	-	-	-	-	10	17.5	18	31.6	57	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	6	20.0	17	56.7	1	3.3	6	20.0	-	-	-	-	30	100.0
	All Sites	2525	91.0	83	3.0	54	1.9	34	1.2	15	0.5	63	2.3	2774	100.0

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur



Report Based on Year of Registration : 2022

TABLE 4(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Groups - Males

As on: 23/05/2024

ICD 10	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	1	16.7	1	16.7	3	50.0	1	16.7	6	100.0
C01-02	Tongue	15	12.0	11	8.8	80	64.0	19	15.2	125	100.0
C03-06	Mouth	23	12.2	18	9.5	111	58.7	37	19.6	189	100.0
C07-08	Salivary Gland	6	30.0	3	15.0	9	45.0	2	10.0	20	100.0
C09	Tonsil	1	33.3	-	-	1	33.3	1	33.3	3	100.0
C10	Oth. Oropharynx	4	3.8	5	4.8	76	72.4	20	19.0	105	100.0
C11	Nasopharynx	1	12.5	1	12.5	5	62.5	1	12.5	8	100.0
C12-13	Hypopharynx	9	12.5	3	4.2	49	68.1	11	15.3	72	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	10	9.1	6	5.5	54	49.1	40	36.4	110	100.0
C16	Stomach	44	23.2	11	5.8	57	30.0	78	41.1	190	100.0
C17	Small Intestine	2	18.2	1	9.1	3	27.3	5	45.5	11	100.0
C18	Colon	30	25.0	19	15.8	31	25.8	40	33.3	120	100.0
C19-20	Rectum	26	15.9	17	10.4	74	45.1	47	28.7	164	100.0
C21	Anus & Anal Canal	1	20.0	1	20.0	3	60.0	-	-	5	100.0
C22	Liver	23	12.4	6	3.2	46	24.9	110	59.5	185	100.0
C23-24	Gallbladder etc.	7	21.2	4	12.1	3	9.1	19	57.6	33	100.0
C25	Pancreas	9	17.3	5	9.6	12	23.1	26	50.0	52	100.0
C30-31	Nose, Sinuses etc.	3	37.5	1	12.5	2	25.0	2	25.0	8	100.0
C32	Larynx	13	10.2	11	8.7	80	63.0	23	18.1	127	100.0
C33-34	Lung etc.	36	6.8	31	5.8	202	37.9	264	49.5	533	100.0
C37-38	Other Thoracic Organs	2	18.2	-	-	7	63.6	2	18.2	11	100.0
C40-41	Bone	8	30.8	3	11.5	9	34.6	6	23.1	26	100.0
C43	Melanoma of Skin	5	35.7	4	28.6	3	21.4	2	14.3	14	100.0
C44	Other Skin	13	31.0	7	16.7	17	40.5	5	11.9	42	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	8	17.4	10	21.7	19	41.3	9	19.6	46	100.0
C50	Breast	1	20.0	3	60.0	1	20.0	-	-	5	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-
C60	Penis	2	28.6	-	-	1	14.3	4	57.1	7	100.0
C61	Prostate	37	26.8	29	21.0	45	32.6	27	19.6	138	100.0
C62	Testis	4	100.0	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	22	39.3	2	3.6	14	25.0	18	32.1	56	100.0
C65	Renal Pelvis	-	-	-	-	2	100.0	-	-	2	100.0
C66	Ureter	1	20.0	-	-	3	60.0	1	20.0	5	100.0
C67	Bladder	33	36.3	32	35.2	12	13.2	14	15.4	91	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	3	37.5	1	12.5	2	25.0	2	25.0	8	100.0
C70-72	Brain, Nervous System	22	36.7	25	41.7	2	3.3	11	18.3	60	100.0
C73	Thyroid	19	24.7	37	48.1	17	22.1	4	5.2	77	100.0
C74	Adrenal Gland	1	33.3	-	-	-	-	2	66.7	3	100.0
C81	Hodgkins Disease	6	35.3	2	11.8	5	29.4	4	23.5	17	100.0
C82-85,C96	NHL	25	15.4	11	6.8	74	45.7	52	32.1	162	100.0
C88	Malig Imn.Prol D	-	-	-	-	1	100.0	-	-	1	100.0
C90	Multiple Myeloma	13	15.7	7	8.4	40	48.2	23	27.7	83	100.0
C91	Lymphoid Leuk.	8	12.7	1	1.6	27	42.9	27	42.9	63	100.0
C92-94	Myeloid Leukaemia	14	18.2	6	7.8	36	46.8	21	27.3	77	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	6	9.2	3	4.6	13	20.0	43	66.2	65	100.0
	All Sites	518	16.5	338	10.8	1251	40.0	1023	32.7	3130	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 4(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Groups - Females

As on: 23/05/2024

ICD 10	Site	Treatment Groups									
		Prior Tmt. Only		Prior & Tmt. at RI		Tmt. Only at RI		No Treatment		Total	
		#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	1	14.3	5	71.4	1	14.3	7	100.0
C01-02	Tongue	6	11.5	4	7.7	35	67.3	7	13.5	52	100.0
C03-06	Mouth	7	8.3	4	4.8	55	65.5	18	21.4	84	100.0
C07-08	Salivary Gland	3	25.0	3	25.0	6	50.0	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	-	6	100.0	6	100.0
C11	Nasopharynx	-	-	-	-	6	85.7	1	14.3	7	100.0
C12-13	Hypopharynx	-	-	-	-	11	61.1	7	38.9	18	100.0
C14	Pharynx Unspecified	-	-	1	100.0	-	-	-	-	1	100.0
C15	Oesophagus	1	2.2	1	2.2	23	50.0	21	45.7	46	100.0
C16	Stomach	11	15.7	6	8.6	28	40.0	25	35.7	70	100.0
C17	Small Intestine	6	42.9	2	14.3	1	7.1	5	35.7	14	100.0
C18	Colon	28	24.6	21	18.4	35	30.7	30	26.3	114	100.0
C19-20	Rectum	15	11.8	12	9.4	60	47.2	40	31.5	127	100.0
C21	Anus & Anal Canal	-	-	-	-	3	60.0	2	40.0	5	100.0
C22	Liver	8	13.1	-	-	14	23.0	39	63.9	61	100.0
C23-24	Gallbladder etc.	3	11.5	4	15.4	5	19.2	14	53.8	26	100.0
C25	Pancreas	7	18.4	-	-	7	18.4	24	63.2	38	100.0
C30-31	Nose, Sinuses etc.	2	28.6	2	28.6	3	42.9	-	-	7	100.0
C32	Larynx	2	16.7	2	16.7	5	41.7	3	25.0	12	100.0
C33-34	Lung etc.	11	9.1	8	6.6	46	38.0	56	46.3	121	100.0
C37-38	Other Thoracic Organs	-	-	1	50.0	1	50.0	-	-	2	100.0
C40-41	Bone	6	35.3	2	11.8	9	52.9	-	-	17	100.0
C43	Melanoma of Skin	4	33.3	3	25.0	4	33.3	1	8.3	12	100.0
C44	Other Skin	11	37.9	10	34.5	4	13.8	4	13.8	29	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	7	20.0	14	40.0	9	25.7	5	14.3	35	100.0
C50	Breast	115	13.4	173	20.2	439	51.3	129	15.1	856	100.0
C51	Vulva	-	-	-	-	2	100.0	-	-	2	100.0
C52	Vagina	1	12.5	2	25.0	5	62.5	-	-	8	100.0
C53	Cervix Uteri	19	11.1	32	18.7	88	51.5	32	18.7	171	100.0
C54	Corpus Uteri	31	18.2	40	23.5	79	46.5	20	11.8	170	100.0
C55	Uterus Unspecified	4	40.0	3	30.0	2	20.0	1	10.0	10	100.0
C56	Ovary etc.	31	18.1	42	24.6	56	32.7	42	24.6	171	100.0
C57	Other Female Genital	1	50.0	1	50.0	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	1	100.0	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	31.2	1	6.2	6	37.5	4	25.0	16	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-
C67	Bladder	6	42.9	4	28.6	1	7.1	3	21.4	14	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-
C69	Eye	4	100.0	-	-	-	-	-	-	4	100.0
C70-72	Brain, Nervous System	13	41.9	13	41.9	1	3.2	4	12.9	31	100.0
C73	Thyroid	70	27.7	123	48.6	43	17.0	17	6.7	253	100.0
C74	Adrenal Gland	3	100.0	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	5	55.6	1	11.1	1	11.1	2	22.2	9	100.0
C82-85,C96	NHL	18	16.5	6	5.5	50	45.9	35	32.1	109	100.0
C88	Malignant Proliferative Disorder	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	2	4.8	4	9.5	21	50.0	15	35.7	42	100.0
C91	Lymphoid Leuk.	3	8.6	2	5.7	16	45.7	14	40.0	35	100.0
C92-94	Myeloid Leukaemia	4	7.0	1	1.8	34	59.6	18	31.6	57	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	6	14.3	-	-	6	14.3	30	71.4	42	100.0
	All Sites	479	16.4	549	18.7	1226	41.9	675	23.0	2929	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur



Report Based on Year of Registration : 2022

TABLE 5(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Males
(Treatment Only at RI)

As on: 23/05/2024

ICD 10	Site	Clinical Extent of Disease											
		Localised		Regional		Distant		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C01-02	Tongue	41	51.2	32	40.0	7	8.8	-	-	-	-	80	100.0
C03-06	Mouth	33	29.7	64	57.7	13	11.7	1	0.9	-	-	111	100.0
C07-08	Salivary Gland	2	22.2	5	55.6	2	22.2	-	-	-	-	9	100.0
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	10	13.2	58	76.3	8	10.5	-	-	-	-	76	100.0
C11	Nasopharynx	-	-	5	100.0	-	-	-	-	-	-	5	100.0
C12-13	Hypopharynx	10	20.4	30	61.2	8	16.3	1	2.0	-	-	49	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	6	11.1	24	44.4	24	44.4	-	-	-	-	54	100.0
C16	Stomach	11	19.3	23	40.4	23	40.4	-	-	-	-	57	100.0
C17	Small Intestine	-	-	3	100.0	-	-	-	-	-	-	3	100.0
C18	Colon	8	25.8	12	38.7	11	35.5	-	-	-	-	31	100.0
C19-20	Rectum	10	13.5	50	67.6	14	18.9	-	-	-	-	74	100.0
C21	Anus & Anal Canal	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C22	Liver	11	23.9	16	34.8	19	41.3	-	-	-	-	46	100.0
C23-24	Gallbladder etc.	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C25	Pancreas	1	8.3	2	16.7	9	75.0	-	-	-	-	12	100.0
C30-31	Nose, Sinuses etc.	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C32	Larynx	46	57.5	31	38.8	3	3.8	-	-	-	-	80	100.0
C33-34	Lung etc.	7	3.5	66	32.7	129	63.9	-	-	-	-	202	100.0
C37-38	Other Thoracic Organs	1	14.3	2	28.6	4	57.1	-	-	-	-	7	100.0
C40-41	Bone	6	66.7	3	33.3	-	-	-	-	-	-	9	100.0
C43	Melanoma of Skin	-	-	3	100.0	-	-	-	-	-	-	3	100.0
C44	Other Skin	10	58.8	6	35.3	-	-	1	5.9	-	-	17	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	10	52.6	6	31.6	2	10.5	1	5.3	-	-	19	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C61	Prostate	13	28.9	4	8.9	27	60.0	1	2.2	-	-	45	100.0
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	6	42.9	2	14.3	6	42.9	-	-	-	-	14	100.0
C65	Renal Pelvis	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C66	Ureter	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C67	Bladder	7	58.3	1	8.3	4	33.3	-	-	-	-	12	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	-	-	-	-	-	-	2	100.0	-	-	2	100.0
C73	Thyroid	5	29.4	7	41.2	5	29.4	-	-	-	-	17	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	-	-	5	100.0	-	-	5	100.0
C82-85, C96	NHL	-	-	1	1.4	-	-	73	98.6	-	-	74	100.0
C88	Malig Imn. Prol D	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C90	Multiple Myeloma	1	2.5	-	-	-	-	39	97.5	-	-	40	100.0
C91	Lymphoid Leuk.	-	-	-	-	-	-	27	100.0	-	-	27	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	36	100.0	-	-	36	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	-	-	5	38.5	6	46.2	2	15.4	-	-	13	100.0
	All Sites	263	21.0	473	37.8	325	26.0	190	15.2	-	-	1251	100.0

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 5(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Females
(Treatment Only at RI)

As on: 23/05/2024

ICD 10	Site	Clinical Extent of Disease										Total	
		Localised		Regional		Distant		Others		Unknown		#	%
		#	%	#	%	#	%	#	%	#	%		
C00	Lip	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C01-02	Tongue	19	54.3	11	31.4	4	11.4	1	2.9	-	-	35	100.0
C03-06	Mouth	20	36.4	30	54.5	5	9.1	-	-	-	-	55	100.0
C07-08	Salivary Gland	4	66.7	1	16.7	1	16.7	-	-	-	-	6	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	-	-	-
C11	Nasopharynx	-	-	6	100.0	-	-	-	-	-	-	6	100.0
C12-13	Hypopharynx	5	45.5	6	54.5	-	-	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	4	17.4	12	52.2	7	30.4	-	-	-	-	23	100.0
C16	Stomach	6	21.4	11	39.3	11	39.3	-	-	-	-	28	100.0
C17	Small Intestine	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C18	Colon	13	37.1	11	31.4	11	31.4	-	-	-	-	35	100.0
C19-20	Rectum	15	25.0	32	53.3	12	20.0	1	1.7	-	-	60	100.0
C21	Anus & Anal Canal	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C22	Liver	1	7.1	2	14.3	11	78.6	-	-	-	-	14	100.0
C23-24	Gallbladder etc.	4	80.0	-	-	1	20.0	-	-	-	-	5	100.0
C25	Pancreas	1	14.3	1	14.3	5	71.4	-	-	-	-	7	100.0
C30-31	Nose, Sinuses etc.	1	33.3	1	33.3	1	33.3	-	-	-	-	3	100.0
C32	Larynx	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C33-34	Lung etc.	1	2.2	5	10.9	40	87.0	-	-	-	-	46	100.0
C37-38	Other Thoracic Organs	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C40-41	Bone	5	55.6	2	22.2	2	22.2	-	-	-	-	9	100.0
C43	Melanoma of Skin	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C44	Other Skin	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	33.3	2	22.2	4	44.4	-	-	-	-	9	100.0
C50	Breast	176	40.1	196	44.6	67	15.3	-	-	-	-	439	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C53	Cervix Uteri	59	67.0	21	23.9	7	8.0	1	1.1	-	-	88	100.0
C54	Corpus Uteri	56	70.9	13	16.5	10	12.7	-	-	-	-	79	100.0
C55	Uterus Unspecified	-	-	1	50.0	1	50.0	-	-	-	-	2	100.0
C56	Ovary etc.	15	26.8	14	25.0	27	48.2	-	-	-	-	56	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	1	100.0	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	3	50.0	2	33.3	1	16.7	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-
C70-72	Brain, Nervous System	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C73	Thyroid	26	60.5	14	32.6	3	7.0	-	-	-	-	43	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C82-85,C96	NHL	-	-	2	4.0	-	-	48	96.0	-	-	50	100.0
C88	Malign. Prol. D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	-	-	-	-	21	100.0	-	-	21	100.0
C91	Lymphoid Leuk.	-	-	-	-	-	-	16	100.0	-	-	16	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	-	-	34	100.0	-	-	34	100.0
C95	Leukaemia Uns.	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns.	-	-	1	16.7	3	50.0	2	33.3	-	-	6	100.0
	All Sites	462	37.7	402	32.8	236	19.2	126	10.3	-	-	1226	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 6(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Males

(Treatment Only at RI)

As on: 23/05/2024

ICD 10	Site	Type of Treatment																				
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Unknown		Total		
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	
C00	Lip	1	33.3	2	66.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100.0
C01-02	Tongue	26	32.5	11	13.8	1	1.2	27	33.8	-	-	6	7.5	9	11.2	-	-	-	-	-	80	100.0
C03-06	Mouth	26	23.4	27	24.3	-	-	44	39.6	-	-	9	8.1	5	4.5	-	-	-	-	-	111	100.0
C07-08	Salivary Gland	-	-	3	33.3	-	-	5	55.6	1	11.1	-	-	-	-	-	-	-	-	-	9	100.0
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	1	1.3	36	47.4	-	-	3	3.9	-	-	35	46.1	1	1.3	-	-	-	-	-	76	100.0
C11	Nasopharynx	-	-	1	20.0	-	-	-	-	-	-	4	80.0	-	-	-	-	-	-	-	5	100.0
C12-13	Hypopharynx	-	-	24	49.0	-	-	-	-	-	-	25	51.0	-	-	-	-	-	-	-	49	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	30	55.6	6	11.1	-	-	1	1.9	15	27.8	2	3.7	-	-	-	-	-	54	100.0
C16	Stomach	4	7.0	11	19.3	12	21.1	1	1.8	26	45.6	2	3.5	1	1.8	-	-	-	-	-	57	100.0
C17	Small Intestine	-	-	-	-	2	66.7	-	-	-	-	1	33.3	-	-	-	-	-	-	-	3	100.0
C18	Colon	11	35.5	1	3.2	8	25.8	-	-	10	32.3	-	-	1	3.2	-	-	-	-	-	31	100.0
C19-20	Rectum	9	12.2	14	18.9	2	2.7	6	8.1	10	13.5	10	13.5	23	31.1	-	-	-	-	-	74	100.0
C21	Anus & Anal Canal	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	1	2.2	11	23.9	29	63.0	-	-	-	-	5	10.9	-	-	-	-	-	-	-	46	100.0
C23-24	Gallbladder etc.	1	33.3	-	-	1	33.3	-	-	1	33.3	-	-	-	-	-	-	-	-	-	3	100.0
C25	Pancreas	2	16.7	1	8.3	5	41.7	-	-	1	8.3	2	16.7	-	-	1	8.3	-	-	-	12	100.0
C30-31	Nose, Sinuses etc.	-	-	1	50.0	-	-	-	-	-	-	1	50.0	-	-	-	-	-	-	-	2	100.0
C32	Larynx	-	-	52	65.0	-	-	5	6.2	-	-	23	28.7	-	-	-	-	-	-	-	80	100.0
C33-34	Lung etc.	1	0.5	126	62.4	17	8.4	-	-	-	-	58	28.7	-	-	-	-	-	-	-	202	100.0
C37-38	Other Thoracic Organs	3	42.9	1	14.3	1	14.3	-	-	1	14.3	1	14.3	-	-	-	-	-	-	-	7	100.0
C40-41	Bone	4	44.4	-	-	2	22.2	-	-	1	11.1	1	11.1	-	-	1	11.1	-	-	-	9	100.0
C43	Melanoma of Skin	3	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100.0
C44	Other Skin	13	76.5	2	11.8	1	5.9	-	-	1	5.9	-	-	-	-	-	-	-	-	-	17	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	6	31.6	1	5.3	-	-	4	21.1	2	10.5	1	5.3	5	26.3	-	-	-	-	-	19	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C61	Prostate	1	2.2	3	6.7	-	-	-	-	1	2.2	-	-	-	-	40	88.9	-	-	-	45	100.0
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	7	50.0	2	14.3	3	21.4	-	-	1	7.1	-	-	1	7.1	-	-	-	-	-	14	100.0
C65	Renal Pelvis	1	50.0	-	-	-	-	-	-	1	50.0	-	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	2	66.7	-	-	-	-	-	-	1	33.3	-	-	-	-	-	-	-	-	-	3	100.0
C67	Bladder	7	58.3	4	33.3	-	-	-	-	1	8.3	-	-	-	-	-	-	-	-	-	12	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	-	-	-	-	-	-	-	-	-	-	2	100.0	-	-	-	-	-	-	-	2	100.0
C73	Thyroid	4	23.5	3	17.6	-	-	9	52.9	-	-	1	5.9	-	-	-	-	-	-	-	17	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	4	80.0	-	-	-	-	1	20.0	-	-	-	-	-	-	-	5	100.0
C82-85,C96	NHL	-	-	5	6.8	60	81.1	-	-	1	1.4	6	8.1	-	-	2	2.7	-	-	-	74	100.0
C88	Malign. Imm. Prol D	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	-	-	3	7.5	35	87.5	-	-	-	-	2	5.0	-	-	-	-	-	-	-	40	100.0
C91	Lymphoid Leuk.	-	-	-	-	20	74.1	-	-	-	-	7	25.9	-	-	-	-	-	-	-	27	100.0
C92-94	Myeloid Leukaemia	-	-	1	2.8	32	88.9	-	-	-	-	1	2.8	-	-	2	5.6	-	-	-	36	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	3	12.5	7	29.2	5	20.8	-	-	3	12.5	5	20.8	-	-	1	4.2	-	-	-	24	100.0
	All Sites	159	12.1	373	28.3	235	17.8	101	7.7	65	4.9	262	19.9	73	5.5	50	3.8	-	-	-	1318	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 6(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Females
(Treatment Only at RI)

As on: 23/05/2024

ICD 10	Site	Type of Treatment																					
		Surgery		R-Therapy		C-Therapy		S+R		S+C		R+C		S+R+C		Others		Unknown		Total			
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
C00	Lip	3	60.0	-	-	-	-	1	20.0	-	-	1	20.0	-	-	-	-	-	-	-	-	5	100.0
C01-02	Tongue	12	34.3	8	22.9	-	-	8	22.9	-	-	1	2.9	6	17.1	-	-	-	-	-	-	35	100.0
C03-06	Mouth	10	18.2	28	50.9	1	1.8	8	14.5	-	-	5	9.1	3	5.5	-	-	-	-	-	-	55	100.0
C07-08	Salivary Gland	2	33.3	1	16.7	-	-	3	50.0	-	-	-	-	-	-	-	-	-	-	-	-	6	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C11	Nasopharynx	-	-	1	16.7	-	-	-	-	-	-	5	83.3	-	-	-	-	-	-	-	-	6	100.0
C12-13	Hypopharynx	-	-	4	36.4	-	-	-	-	-	-	7	63.6	-	-	-	-	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	-	-	15	65.2	1	4.3	-	-	1	4.3	4	17.4	2	8.7	-	-	-	-	-	-	23	100.0
C16	Stomach	5	17.9	2	7.1	11	39.3	-	-	9	32.1	-	-	1	3.6	-	-	-	-	-	-	28	100.0
C17	Small Intestine	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C18	Colon	17	48.6	-	-	2	5.7	-	-	16	45.7	-	-	-	-	-	-	-	-	-	-	35	100.0
C19-20	Rectum	11	18.3	15	25.0	3	5.0	4	6.7	1	1.7	4	6.7	22	36.7	-	-	-	-	-	-	60	100.0
C21	Anus & Anal Canal	-	-	1	33.3	-	-	1	33.3	-	-	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	-	-	3	21.4	8	57.1	-	-	1	7.1	1	7.1	1	7.1	-	-	-	-	-	-	14	100.0
C23-24	Gallbladder etc.	2	40.0	-	-	1	20.0	-	-	2	40.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C25	Pancreas	-	-	-	-	6	85.7	-	-	1	14.3	-	-	-	-	-	-	-	-	-	-	7	100.0
C30-31	Nose, Sinuses etc.	-	-	1	33.3	1	33.3	1	33.3	-	-	-	-	-	-	-	-	-	-	-	-	3	100.0
C32	Larynx	-	-	4	80.0	-	-	-	-	-	-	1	20.0	-	-	-	-	-	-	-	-	5	100.0
C33-34	Lung etc.	-	-	21	45.7	19	41.3	-	-	-	-	6	13.0	-	-	-	-	-	-	-	-	46	100.0
C37-38	Other Thoracic Organs	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C40-41	Bone	1	11.1	2	22.2	-	-	-	-	4	44.4	-	-	2	22.2	-	-	-	-	-	-	9	100.0
C43	Melanoma of Skin	4	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	100.0
C44	Other Skin	2	50.0	2	50.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	2	22.2	1	11.1	1	11.1	1	11.1	1	11.1	3	33.3	-	-	-	-	-	-	-	-	9	100.0
C50	Breast	6	1.4	5	1.1	5	1.1	2	0.5	17	3.9	1	0.2	43	9.8	360	82.0	-	-	-	-	439	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	2	40.0	3	60.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	100.0
C53	Cervix Uteri	3	3.4	28	31.8	-	-	1	1.1	-	-	55	62.5	1	1.1	-	-	-	-	-	-	88	100.0
C54	Corpus Uteri	34	43.0	1	1.3	6	7.6	17	21.5	6	7.6	5	6.3	10	12.7	-	-	-	-	-	-	79	100.0
C55	Uterus Unspecified	-	-	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C56	Ovary etc.	6	10.7	-	-	14	25.0	-	-	34	60.7	1	1.8	1	1.8	-	-	-	-	-	-	56	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	83.3	1	16.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C70-72	Brain, Nervous System	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	17	39.5	3	7.0	-	-	23	53.5	-	-	-	-	-	-	-	-	-	-	-	-	43	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C82-85,C96	NHL	1	2.0	5	10.0	37	74.0	-	-	1	2.0	6	12.0	-	-	-	-	-	-	-	-	50	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	5	23.8	15	71.4	-	-	-	-	1	4.8	-	-	-	-	-	-	-	-	21	100.0
C91	Lymphoid Leuk.	1	6.2	1	6.2	10	62.5	-	-	-	-	4	25.0	-	-	-	-	-	-	-	-	16	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	33	97.1	-	-	-	-	-	-	-	-	-	-	1	2.9	-	-	34	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	3	25.0	4	33.3	3	25.0	-	-	1	8.3	1	8.3	-	-	-	-	-	-	-	-	12	100.0
	All Sites	161	11.6	150	10.8	187	13.5	84	6.1	103	7.4	163	11.8	96	6.9	439	31.7	-	-	-	-	1383	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 7(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Males

(Treatment Only at RI)

As on: 23/05/2024

ICD 10	Site	Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	33.3	2	66.7	-	-	-	-	-	-	-	-	3	100.0
C01-02	Tongue	62	47.3	53	40.5	16	12.2	-	-	-	-	-	-	131	100.0
C03-06	Mouth	75	43.1	85	48.9	14	8.0	-	-	-	-	-	-	174	100.0
C07-08	Salivary Gland	6	40.0	8	53.3	1	6.7	-	-	-	-	-	-	15	100.0
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	5	4.3	75	64.7	36	31.0	-	-	-	-	-	-	116	100.0
C11	Nasopharynx	-	-	5	55.6	4	44.4	-	-	-	-	-	-	9	100.0
C12-13	Hypopharynx	-	-	49	66.2	25	33.8	-	-	-	-	-	-	74	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	3	4.1	47	63.5	24	32.4	-	-	-	-	-	-	74	100.0
C16	Stomach	32	36.4	15	17.0	41	46.6	-	-	-	-	-	-	88	100.0
C17	Small Intestine	-	-	1	25.0	3	75.0	-	-	-	-	-	-	4	100.0
C18	Colon	22	51.2	2	4.7	19	44.2	-	-	-	-	-	-	43	100.0
C19-20	Rectum	48	32.9	53	36.3	45	30.8	-	-	-	-	-	-	146	100.0
C21	Anus & Anal Canal	-	-	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	1	2.0	16	31.4	34	66.7	-	-	-	-	-	-	51	100.0
C23-24	Gallbladder etc.	2	50.0	-	-	2	50.0	-	-	-	-	-	-	4	100.0
C25	Pancreas	4	23.5	4	23.5	8	47.1	1	5.9	-	-	-	-	17	100.0
C30-31	Nose, Sinuses etc.	-	-	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C32	Larynx	5	4.6	80	74.1	23	21.3	-	-	-	-	-	-	108	100.0
C33-34	Lung etc.	1	0.4	184	70.8	75	28.8	-	-	-	-	-	-	260	100.0
C37-38	Other Thoracic Organs	4	44.4	2	22.2	3	33.3	-	-	-	-	-	-	9	100.0
C40-41	Bone	5	45.5	1	9.1	4	36.4	1	9.1	-	-	-	-	11	100.0
C43	Melanoma of Skin	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C44	Other Skin	14	77.8	2	11.1	2	11.1	-	-	-	-	-	-	18	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	17	47.2	11	30.6	8	22.2	-	-	-	-	-	-	36	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	50.0	1	50.0	-	-	-	-	-	-	-	-	2	100.0
C61	Prostate	3	4.0	23	30.7	9	12.0	40	53.3	-	-	-	-	75	100.0
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	9	52.9	3	17.6	5	29.4	-	-	-	-	-	-	17	100.0
C65	Renal Pelvis	2	66.7	-	-	1	33.3	-	-	-	-	-	-	3	100.0
C66	Ureter	3	75.0	-	-	1	25.0	-	-	-	-	-	-	4	100.0
C67	Bladder	8	61.5	4	30.8	1	7.7	-	-	-	-	-	-	13	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	-	-	2	50.0	2	50.0	-	-	-	-	-	-	4	100.0
C73	Thyroid	13	48.1	13	48.1	1	3.7	-	-	-	-	-	-	27	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	1	16.7	5	83.3	-	-	-	-	-	-	6	100.0
C82-85,C96	NHL	1	1.2	12	14.6	67	81.7	1	1.2	1	1.2	-	-	82	100.0
C88	Malign.Imn.Prol D	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	-	-	5	11.9	37	88.1	-	-	-	-	-	-	42	100.0
C91	Lymphoid Leuk.	-	-	7	20.6	27	79.4	-	-	-	-	-	-	34	100.0
C92-94	Myeloid Leukaemia	-	-	2	5.4	33	89.2	-	-	2	5.4	-	-	37	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	7.1	11	78.6	2	14.3	-	-	-	-	-	-	14	100.0
	All Sites	352	19.9	785	44.5	582	33.0	43	2.4	3	0.2	-	-	1765	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 7(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Females
(Treatment Only at RI)

As on: 23/05/2024

ICD 10	Site	Any S		Any R		Any C		Any H		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	4	57.1	2	28.6	1	14.3	-	-	-	-	-	-	7	100.0
C01-02	Tongue	26	46.4	23	41.1	7	12.5	-	-	-	-	-	-	56	100.0
C03-06	Mouth	21	28.4	44	59.5	9	12.2	-	-	-	-	-	-	74	100.0
C07-08	Salivary Gland	5	55.6	4	44.4	-	-	-	-	-	-	-	-	9	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C11	Nasopharynx	-	-	6	54.5	5	45.5	-	-	-	-	-	-	11	100.0
C12-13	Hypopharynx	-	-	11	61.1	7	38.9	-	-	-	-	-	-	18	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	3	9.4	21	65.6	8	25.0	-	-	-	-	-	-	32	100.0
C16	Stomach	15	38.5	3	7.7	21	53.8	-	-	-	-	-	-	39	100.0
C17	Small Intestine	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C18	Colon	33	64.7	-	-	18	35.3	-	-	-	-	-	-	51	100.0
C19-20	Rectum	38	33.6	45	39.8	30	26.5	-	-	-	-	-	-	113	100.0
C21	Anus & Anal Canal	1	20.0	3	60.0	1	20.0	-	-	-	-	-	-	5	100.0
C22	Liver	2	11.1	5	27.8	11	61.1	-	-	-	-	-	-	18	100.0
C23-24	Gallbladder etc.	4	57.1	-	-	3	42.9	-	-	-	-	-	-	7	100.0
C25	Pancreas	1	12.5	-	-	7	87.5	-	-	-	-	-	-	8	100.0
C30-31	Nose, Sinuses etc.	1	25.0	2	50.0	1	25.0	-	-	-	-	-	-	4	100.0
C32	Larynx	-	-	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C33-34	Lung etc.	-	-	27	51.9	25	48.1	-	-	-	-	-	-	52	100.0
C37-38	Other Thoracic Organs	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C40-41	Bone	7	41.2	4	23.5	6	35.3	-	-	-	-	-	-	17	100.0
C43	Melanoma of Skin	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C44	Other Skin	2	50.0	2	50.0	-	-	-	-	-	-	-	-	4	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	4	28.6	5	35.7	5	35.7	-	-	-	-	-	-	14	100.0
C50	Breast	367	26.4	312	22.4	351	25.3	360	25.9	-	-	-	-	1390	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	2	40.0	3	60.0	-	-	-	-	-	-	-	-	5	100.0
C53	Cervix Uteri	5	3.4	85	58.2	56	38.4	-	-	-	-	-	-	146	100.0
C54	Corpus Uteri	67	52.8	33	26.0	27	21.3	-	-	-	-	-	-	127	100.0
C55	Uterus Unspecified	-	-	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C56	Ovary etc.	41	44.1	2	2.2	50	53.8	-	-	-	-	-	-	93	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	1	50.0	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	83.3	1	16.7	-	-	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C70-72	Brain, Nervous System	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C73	Thyroid	40	60.6	26	39.4	-	-	-	-	-	-	-	-	66	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C82-85,C96	NHL	2	3.5	11	19.3	44	77.2	-	-	-	-	-	-	57	100.0
C88	Malig Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	-	-	6	27.3	16	72.7	-	-	-	-	-	-	22	100.0
C91	Lymphoid Leuk.	1	5.0	5	25.0	14	70.0	-	-	-	-	-	-	20	100.0
C92-94	Myeloid Leukaemia	-	-	-	-	33	97.1	-	-	1	2.9	-	-	34	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	14.3	2	28.6	4	57.1	-	-	-	-	-	-	7	100.0
	All Sites	708	27.9	699	27.6	766	30.2	360	14.2	1	0.0	-	-	2534	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 8(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) - Males

As on: 23/05/2024

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	3	75.0	-	-	-	-	1	25.0	-	-	4	100.0
C01-02	Tongue	80	80.8	6	6.1	12	12.1	1	1.0	-	-	99	100.0
C03-06	Mouth	111	75.0	23	15.5	11	7.4	3	2.0	-	-	148	100.0
C07-08	Salivary Gland	9	81.8	2	18.2	-	-	-	-	-	-	11	100.0
C09	Tonsil	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C10	Oth. Oropharynx	76	79.2	6	6.2	12	12.5	2	2.1	-	-	96	100.0
C11	Nasopharynx	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C12-13	Hypopharynx	49	81.7	7	11.7	4	6.7	-	-	-	-	60	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	54	57.4	20	21.3	19	20.2	1	1.1	-	-	94	100.0
C16	Stomach	57	42.2	53	39.3	20	14.8	5	3.7	-	-	135	100.0
C17	Small Intestine	3	37.5	3	37.5	2	25.0	-	-	-	-	8	100.0
C18	Colon	31	43.7	28	39.4	12	16.9	-	-	-	-	71	100.0
C19-20	Rectum	74	61.2	23	19.0	22	18.2	2	1.7	-	-	121	100.0
C21	Anus & Anal Canal	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C22	Liver	46	29.5	92	59.0	13	8.3	5	3.2	-	-	156	100.0
C23-24	Gallbladder etc.	3	13.6	15	68.2	4	18.2	-	-	-	-	22	100.0
C25	Pancreas	12	31.6	20	52.6	6	15.8	-	-	-	-	38	100.0
C30-31	Nose, Sinuses etc.	2	50.0	1	25.0	-	-	1	25.0	-	-	4	100.0
C32	Larynx	80	77.7	10	9.7	13	12.6	-	-	-	-	103	100.0
C33-34	Lung etc.	202	43.3	194	41.6	64	13.7	6	1.3	-	-	466	100.0
C37-38	Other Thoracic Organs	7	77.8	2	22.2	-	-	-	-	-	-	9	100.0
C40-41	Bone	9	60.0	4	26.7	2	13.3	-	-	-	-	15	100.0
C43	Melanoma of Skin	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C44	Other Skin	17	77.3	3	13.6	2	9.1	-	-	-	-	22	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	19	67.9	5	17.9	4	14.3	-	-	-	-	28	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	20.0	4	80.0	-	-	-	-	-	-	5	100.0
C61	Prostate	45	62.5	17	23.6	9	12.5	1	1.4	-	-	72	100.0
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	14	43.8	13	40.6	5	15.6	-	-	-	-	32	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	3	75.0	1	25.0	-	-	-	-	-	-	4	100.0
C67	Bladder	12	46.2	9	34.6	5	19.2	-	-	-	-	26	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	50.0	1	25.0	-	-	1	25.0	-	-	4	100.0
C70-72	Brain, Nervous System	2	15.4	7	53.8	4	30.8	-	-	-	-	13	100.0
C73	Thyroid	17	81.0	4	19.0	-	-	-	-	-	-	21	100.0
C74	Adrenal Gland	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C81	Hodgkins Disease	5	55.6	3	33.3	1	11.1	-	-	-	-	9	100.0
C82-85,C96	NHL	74	58.7	46	36.5	1	0.8	5	4.0	-	-	126	100.0
C88	Malig Imn.Prol D	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	40	63.5	15	23.8	3	4.8	5	7.9	-	-	63	100.0
C91	Lymphoid Leuk.	27	50.0	19	35.2	-	-	8	14.8	-	-	54	100.0
C92-94	Myeloid Leukaemia	36	63.2	16	28.1	-	-	5	8.8	-	-	57	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	13	23.2	43	76.8	-	-	-	-	-	-	56	100.0
	All Sites	1251	55.0	721	31.7	250	11.0	52	2.3	-	-	2274	100.0

C8 & U: C86, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2022

TABLE 8(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) - Females

As on: 23/05/2024

ICD 10	Site	Received		Not Received		Not Accepted		Incomplete		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	5	83.3	-	-	-	-	1	16.7	-	-	6	100.0
C01-02	Tongue	35	83.3	3	7.1	3	7.1	1	2.4	-	-	42	100.0
C03-06	Mouth	55	75.3	11	15.1	5	6.8	2	2.7	-	-	73	100.0
C07-08	Salivary Gland	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	2	33.3	4	66.7	-	-	6	100.0
C11	Nasopharynx	6	85.7	-	-	1	14.3	-	-	-	-	7	100.0
C12-13	Hypopharynx	11	61.1	5	27.8	2	11.1	-	-	-	-	18	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	23	52.3	15	34.1	6	13.6	-	-	-	-	44	100.0
C16	Stomach	28	52.8	16	30.2	6	11.3	3	5.7	-	-	53	100.0
C17	Small Intestine	1	16.7	4	66.7	1	16.7	-	-	-	-	6	100.0
C18	Colon	35	53.8	25	38.5	3	4.6	2	3.1	-	-	65	100.0
C19-20	Rectum	60	60.0	27	27.0	13	13.0	-	-	-	-	100	100.0
C21	Anus & Anal Canal	3	60.0	-	-	2	40.0	-	-	-	-	5	100.0
C22	Liver	14	26.4	32	60.4	7	13.2	-	-	-	-	53	100.0
C23-24	Gallbladder etc.	5	26.3	10	52.6	4	21.1	-	-	-	-	19	100.0
C25	Pancreas	7	22.6	19	61.3	4	12.9	1	3.2	-	-	31	100.0
C30-31	Nose, Sinuses etc.	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C32	Larynx	5	62.5	2	25.0	-	-	1	12.5	-	-	8	100.0
C33-34	Lung etc.	46	45.1	43	42.2	11	10.8	2	2.0	-	-	102	100.0
C37-38	Other Thoracic Organs	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C40-41	Bone	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C43	Melanoma of Skin	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C44	Other Skin	4	50.0	3	37.5	1	12.5	-	-	-	-	8	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	9	64.3	5	35.7	-	-	-	-	-	-	14	100.0
C50	Breast	439	77.3	58	10.2	37	6.5	34	6.0	-	-	568	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C53	Cervix Uteri	88	73.3	15	12.5	16	13.3	1	0.8	-	-	120	100.0
C54	Corpus Uteri	79	79.8	11	11.1	6	6.1	3	3.0	-	-	99	100.0
C55	Uterus Unspecified	2	66.7	-	-	1	33.3	-	-	-	-	3	100.0
C56	Ovary etc.	56	57.1	25	25.5	9	9.2	8	8.2	-	-	98	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	6	60.0	3	30.0	1	10.0	-	-	-	-	10	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	25.0	1	25.0	2	50.0	-	-	-	-	4	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-
C70-72	Brain, Nervous System	1	20.0	3	60.0	1	20.0	-	-	-	-	5	100.0
C73	Thyroid	43	71.7	12	20.0	4	6.7	1	1.7	-	-	60	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C82-85,C96	NHL	50	58.8	31	36.5	1	1.2	3	3.5	-	-	85	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	21	58.3	11	30.6	-	-	4	11.1	-	-	36	100.0
C91	Lymphoid Leuk.	16	53.3	10	33.3	-	-	4	13.3	-	-	30	100.0
C92-94	Myeloid Leukaemia	34	65.4	11	21.2	-	-	7	13.5	-	-	52	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	6	16.7	27	75.0	3	8.3	-	-	-	-	36	100.0
	All Sites	1226	64.5	441	23.2	152	8.0	82	4.3	-	-	1901	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

**TABLE 9(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution
(Excluding the Cancers Previously Treated) - Males**

As on: 23/05/2024

ICD 10	Site	Radical		Palliative		Pain Relief Only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C01-02	Tongue	63	78.8	17	21.2	-	-	-	-	-	-	80	100.0
C03-06	Mouth	77	69.4	34	30.6	-	-	-	-	-	-	111	100.0
C07-08	Salivary Gland	6	66.7	3	33.3	-	-	-	-	-	-	9	100.0
C09	Tonsil	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C10	Oth. Oropharynx	40	52.6	36	47.4	-	-	-	-	-	-	76	100.0
C11	Nasopharynx	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C12-13	Hypopharynx	24	49.0	25	51.0	-	-	-	-	-	-	49	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	15	27.8	38	70.4	-	-	1	1.9	-	-	54	100.0
C16	Stomach	32	56.1	25	43.9	-	-	-	-	-	-	57	100.0
C17	Small Intestine	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C18	Colon	21	67.7	10	32.3	-	-	-	-	-	-	31	100.0
C19-20	Rectum	57	77.0	17	23.0	-	-	-	-	-	-	74	100.0
C21	Anus & Anal Canal	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C22	Liver	8	17.4	38	82.6	-	-	-	-	-	-	46	100.0
C23-24	Gallbladder etc.	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C25	Pancreas	4	33.3	8	66.7	-	-	-	-	-	-	12	100.0
C30-31	Nose, Sinuses etc.	-	-	2	100.0	-	-	-	-	-	-	2	100.0
C32	Larynx	58	72.5	22	27.5	-	-	-	-	-	-	80	100.0
C33-34	Lung etc.	27	13.4	175	86.6	-	-	-	-	-	-	202	100.0
C37-38	Other Thoracic Organs	3	42.9	4	57.1	-	-	-	-	-	-	7	100.0
C40-41	Bone	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C43	Melanoma of Skin	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C44	Other Skin	14	82.4	3	17.6	-	-	-	-	-	-	17	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	18	94.7	1	5.3	-	-	-	-	-	-	19	100.0
C50	Breast	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C61	Prostate	31	68.9	14	31.1	-	-	-	-	-	-	45	100.0
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	9	64.3	5	35.7	-	-	-	-	-	-	14	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	3	100.0	-	-	-	-	-	-	-	-	3	100.0
C67	Bladder	8	66.7	4	33.3	-	-	-	-	-	-	12	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C70-72	Brain, Nervous System	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C73	Thyroid	13	76.5	4	23.5	-	-	-	-	-	-	17	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C82-85,C96	NHL	68	91.9	6	8.1	-	-	-	-	-	-	74	100.0
C88	Malig Imn.Prol D	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	35	87.5	5	12.5	-	-	-	-	-	-	40	100.0
C91	Lymphoid Leuk.	25	92.6	2	7.4	-	-	-	-	-	-	27	100.0
C92-94	Myeloid Leukaemia	33	91.7	3	8.3	-	-	-	-	-	-	36	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	2	15.4	11	84.6	-	-	-	-	-	-	13	100.0
	All Sites	729	58.3	521	41.6	-	-	1	0.1	-	-	1251	100.0

26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2022

**TABLE 9(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution
(Excluding the Cancers Previously Treated) - Females**

As on: 23/05/2024

ICD 10	Site	Radical		Palliative		Pain Relief Only		Symptomatic		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C01-02	Tongue	26	74.3	9	25.7	-	-	-	-	-	-	35	100.0
C03-06	Mouth	22	40.0	33	60.0	-	-	-	-	-	-	55	100.0
C07-08	Salivary Gland	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	-	-	-	-	-	-	-	-	-	-
C11	Nasopharynx	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C12-13	Hypopharynx	6	54.5	5	45.5	-	-	-	-	-	-	11	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	5	21.7	18	78.3	-	-	-	-	-	-	23	100.0
C16	Stomach	13	46.4	15	53.6	-	-	-	-	-	-	28	100.0
C17	Small Intestine	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C18	Colon	30	85.7	4	11.4	-	-	1	2.9	-	-	35	100.0
C19-20	Rectum	47	78.3	13	21.7	-	-	-	-	-	-	60	100.0
C21	Anus & Anal Canal	2	66.7	1	33.3	-	-	-	-	-	-	3	100.0
C22	Liver	5	35.7	9	64.3	-	-	-	-	-	-	14	100.0
C23-24	Gallbladder etc.	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C25	Pancreas	2	28.6	5	71.4	-	-	-	-	-	-	7	100.0
C30-31	Nose, Sinuses etc.	1	33.3	1	33.3	1	33.3	-	-	-	-	3	100.0
C32	Larynx	4	80.0	1	20.0	-	-	-	-	-	-	5	100.0
C33-34	Lung etc.	3	6.5	43	93.5	-	-	-	-	-	-	46	100.0
C37-38	Other Thoracic Organs	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C40-41	Bone	9	100.0	-	-	-	-	-	-	-	-	9	100.0
C43	Melanoma of Skin	4	100.0	-	-	-	-	-	-	-	-	4	100.0
C44	Other Skin	2	50.0	2	50.0	-	-	-	-	-	-	4	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	5	55.6	4	44.4	-	-	-	-	-	-	9	100.0
C50	Breast	380	86.6	58	13.2	-	-	1	0.2	-	-	439	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	3	60.0	2	40.0	-	-	-	-	-	-	5	100.0
C53	Cervix Uteri	65	73.9	23	26.1	-	-	-	-	-	-	88	100.0
C54	Corpus Uteri	68	86.1	11	13.9	-	-	-	-	-	-	79	100.0
C55	Uterus Unspecified	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C56	Ovary etc.	47	83.9	9	16.1	-	-	-	-	-	-	56	100.0
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	83.3	1	16.7	-	-	-	-	-	-	6	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	-	-	-	-	-	-	-	-	-	-
C70-72	Brain, Nervous System	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C73	Thyroid	41	95.3	2	4.7	-	-	-	-	-	-	43	100.0
C74	Adrenal Gland	-	-	-	-	-	-	-	-	-	-	-	-
C81	Hodgkins Disease	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C82-85,C96	NHL	40	80.0	9	18.0	1	2.0	-	-	-	-	50	100.0
C88	Malig Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	13	61.9	8	38.1	-	-	-	-	-	-	21	100.0
C91	Lymphoid Leuk.	14	87.5	2	12.5	-	-	-	-	-	-	16	100.0
C92-94	Myeloid Leukaemia	30	88.2	4	11.8	-	-	-	-	-	-	34	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	1	16.7	5	83.3	-	-	-	-	-	-	6	100.0
	All Sites	918	74.9	304	24.8	2	0.2	2	0.2	-	-	1226	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)

Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur



Report Based on Year of Registration : 2022

TABLE 10(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status - Males

As on: 23/05/2024

ICD 10	Site	Unmarried		Married		Widowed		Divorced		Separated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	6	100.0	-	-	-	-	-	-	-	-	-	-	6	100.0
C01-02	Tongue	8	6.4	116	92.8	-	-	1	0.8	-	-	-	-	-	-	125	100.0
C03-06	Mouth	4	2.1	185	97.9	-	-	-	-	-	-	-	-	-	-	189	100.0
C07-08	Salivary Gland	1	5.0	19	95.0	-	-	-	-	-	-	-	-	-	-	20	100.0
C09	Tonsil	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	7	6.7	96	91.4	1	1.0	1	1.0	-	-	-	-	-	-	105	100.0
C11	Nasopharynx	1	12.5	7	87.5	-	-	-	-	-	-	-	-	-	-	8	100.0
C12-13	Hypopharynx	5	6.9	65	90.3	-	-	2	2.8	-	-	-	-	-	-	72	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	5	4.5	105	95.5	-	-	-	-	-	-	-	-	-	-	110	100.0
C16	Stomach	2	1.1	187	98.4	1	0.5	-	-	-	-	-	-	-	-	190	100.0
C17	Small Intestine	-	-	11	100.0	-	-	-	-	-	-	-	-	-	-	11	100.0
C18	Colon	2	1.7	117	97.5	-	-	1	0.8	-	-	-	-	-	-	120	100.0
C19-20	Rectum	2	1.2	162	98.8	-	-	-	-	-	-	-	-	-	-	164	100.0
C21	Anus & Anal Canal	-	-	3	60.0	2	40.0	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	5	2.7	178	96.2	2	1.1	-	-	-	-	-	-	-	-	185	100.0
C23-24	Gallbladder etc.	1	3.0	32	97.0	-	-	-	-	-	-	-	-	-	-	33	100.0
C25	Pancreas	2	3.8	48	92.3	1	1.9	1	1.9	-	-	-	-	-	-	52	100.0
C30-31	Nose, Sinuses etc.	1	12.5	6	75.0	-	-	1	12.5	-	-	-	-	-	-	8	100.0
C32	Larynx	3	2.4	120	94.5	4	3.1	-	-	-	-	-	-	-	-	127	100.0
C33-34	Lung etc.	8	1.5	521	97.7	4	0.8	-	-	-	-	-	-	-	-	533	100.0
C37-38	Other Thoracic Organs	1	9.1	9	81.8	1	9.1	-	-	-	-	-	-	-	-	11	100.0
C40-41	Bone	9	34.6	17	65.4	-	-	-	-	-	-	-	-	-	-	26	100.0
C43	Melanoma of Skin	1	7.1	13	92.9	-	-	-	-	-	-	-	-	-	-	14	100.0
C44	Other Skin	3	7.1	39	92.9	-	-	-	-	-	-	-	-	-	-	42	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	3	6.5	43	93.5	-	-	-	-	-	-	-	-	-	-	46	100.0
C50	Breast	-	-	5	100.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	1	14.3	5	71.4	-	-	1	14.3	-	-	-	-	-	-	7	100.0
C61	Prostate	1	0.7	137	99.3	-	-	-	-	-	-	-	-	-	-	138	100.0
C62	Testis	-	-	4	100.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	4	7.1	52	92.9	-	-	-	-	-	-	-	-	-	-	56	100.0
C65	Renal Pelvis	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	1	20.0	4	80.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C67	Bladder	1	1.1	90	98.9	-	-	-	-	-	-	-	-	-	-	91	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	7	87.5	1	12.5	-	-	-	-	-	-	-	-	-	-	8	100.0
C70-72	Brain, Nervous System	14	23.3	46	76.7	-	-	-	-	-	-	-	-	-	-	60	100.0
C73	Thyroid	7	9.1	70	90.9	-	-	-	-	-	-	-	-	-	-	77	100.0
C74	Adrenal Gland	1	33.3	2	66.7	-	-	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	5	29.4	12	70.6	-	-	-	-	-	-	-	-	-	-	17	100.0
C82-85,C96	NHL	15	9.3	146	90.1	1	0.6	-	-	-	-	-	-	-	-	162	100.0
C88	Malig Imm.Prol D	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	2	2.4	81	97.6	-	-	-	-	-	-	-	-	-	-	83	100.0
C91	Lymphoid Leuk.	23	36.5	40	63.5	-	-	-	-	-	-	-	-	-	-	63	100.0
C92-94	Myeloid Leukaemia	18	23.4	59	76.6	-	-	-	-	-	-	-	-	-	-	77	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	2	3.1	62	95.4	1	1.5	-	-	-	-	-	-	-	-	65	100.0
	All Sites	176	5.6	2928	93.5	18	0.6	8	0.3	-	-	-	-	-	-	3130	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 10(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status - Females

As on: 23/05/2024

ICD 10	Site	Unmarried		Married		Widowed		Divorced		Separated		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	-	-	5	71.4	2	28.6	-	-	-	-	-	-	-	-	7	100.0
C01-02	Tongue	-	-	41	78.8	10	19.2	1	1.9	-	-	-	-	-	-	52	100.0
C03-06	Mouth	1	1.2	63	75.0	19	22.6	1	1.2	-	-	-	-	-	-	84	100.0
C07-08	Salivary Gland	1	8.3	9	75.0	1	8.3	1	8.3	-	-	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	-	-	3	50.0	3	50.0	-	-	-	-	-	-	-	-	6	100.0
C11	Nasopharynx	1	14.3	5	71.4	1	14.3	-	-	-	-	-	-	-	-	7	100.0
C12-13	Hypopharynx	2	11.1	14	77.8	2	11.1	-	-	-	-	-	-	-	-	18	100.0
C14	Pharynx Unspecified	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	2	4.3	38	82.6	5	10.9	-	-	-	-	-	-	1	2.2	46	100.0
C16	Stomach	2	2.9	61	87.1	7	10.0	-	-	-	-	-	-	-	-	70	100.0
C17	Small Intestine	1	7.1	11	78.6	2	14.3	-	-	-	-	-	-	-	-	14	100.0
C18	Colon	4	3.5	93	81.6	15	13.2	2	1.8	-	-	-	-	-	-	114	100.0
C19-20	Rectum	6	4.7	103	81.1	17	13.4	1	0.8	-	-	-	-	-	-	127	100.0
C21	Anus & Anal Canal	1	20.0	2	40.0	2	40.0	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	2	3.3	49	80.3	9	14.8	1	1.6	-	-	-	-	-	-	61	100.0
C23-24	Gallbladder etc.	-	-	24	92.3	1	3.8	1	3.8	-	-	-	-	-	-	26	100.0
C25	Pancreas	1	2.6	29	76.3	8	21.1	-	-	-	-	-	-	-	-	38	100.0
C30-31	Nose, Sinuses etc.	1	14.3	6	85.7	-	-	-	-	-	-	-	-	-	-	7	100.0
C32	Larynx	-	-	10	83.3	2	16.7	-	-	-	-	-	-	-	-	12	100.0
C33-34	Lung etc.	8	6.6	96	79.3	17	14.0	-	-	-	-	-	-	-	-	121	100.0
C37-38	Other Thoracic Organs	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	6	35.3	11	64.7	-	-	-	-	-	-	-	-	-	-	17	100.0
C43	Melanoma of Skin	1	8.3	11	91.7	-	-	-	-	-	-	-	-	-	-	12	100.0
C44	Other Skin	2	6.9	24	82.8	3	10.3	-	-	-	-	-	-	-	-	29	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	4	11.4	25	71.4	5	14.3	1	2.9	-	-	-	-	-	-	35	100.0
C50	Breast	34	4.0	751	87.7	58	6.8	12	1.4	1	0.1	-	-	-	-	856	100.0
C51	Vulva	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	-	-	7	87.5	1	12.5	-	-	-	-	-	-	-	-	8	100.0
C53	Cervix Uteri	3	1.8	144	84.2	24	14.0	-	-	-	-	-	-	-	-	171	100.0
C54	Corpus Uteri	7	4.1	147	86.5	16	9.4	-	-	-	-	-	-	-	-	170	100.0
C55	Uterus Unspecified	1	10.0	9	90.0	-	-	-	-	-	-	-	-	-	-	10	100.0
C56	Ovary etc.	16	9.4	141	82.5	14	8.2	-	-	-	-	-	-	-	-	171	100.0
C57	Other Female Genital	-	-	2	100.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	-	-	16	100.0	-	-	-	-	-	-	-	-	-	-	16	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	1	7.1	11	78.6	2	14.3	-	-	-	-	-	-	-	-	14	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	3	75.0	1	25.0	-	-	-	-	-	-	-	-	-	-	4	100.0
C70-72	Brain, Nervous System	3	9.7	27	87.1	1	3.2	-	-	-	-	-	-	-	-	31	100.0
C73	Thyroid	12	4.7	219	86.6	19	7.5	3	1.2	-	-	-	-	-	-	253	100.0
C74	Adrenal Gland	-	-	3	100.0	-	-	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	-	-	8	88.9	1	11.1	-	-	-	-	-	-	-	-	9	100.0
C82-85,C96	NHL	5	4.6	96	88.1	7	6.4	1	0.9	-	-	-	-	-	-	109	100.0
C88	Malign.Imn.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	1	2.4	35	83.3	6	14.3	-	-	-	-	-	-	-	-	42	100.0
C91	Lymphoid Leuk.	9	25.7	24	68.6	2	5.7	-	-	-	-	-	-	-	-	35	100.0
C92-94	Myeloid Leukaemia	8	14.0	46	80.7	2	3.5	1	1.8	-	-	-	-	-	-	57	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	3	7.1	35	83.3	2	4.8	2	4.8	-	-	-	-	-	-	42	100.0
	All Sites	152	5.2	2461	84.0	286	9.8	28	1.0	1	0.0	-	-	1	0.0	2929	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 12(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion - Males

As on: 23/05/2024

ICD 10	Site	Hindu		Muslim		Christian		Neo-Budhist		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	5	83.3	-	-	1	16.7	-	-	-	-	-	-	6	100.0
C01-02	Tongue	96	76.8	20	16.0	7	5.6	-	-	-	-	2	1.6	125	100.0
C03-06	Mouth	120	63.5	47	24.9	22	11.6	-	-	-	-	-	-	189	100.0
C07-08	Salivary Gland	13	65.0	5	25.0	2	10.0	-	-	-	-	-	-	20	100.0
C09	Tonsil	2	66.7	-	-	1	33.3	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	87	82.9	10	9.5	8	7.6	-	-	-	-	-	-	105	100.0
C11	Nasopharynx	2	25.0	3	37.5	2	25.0	-	-	-	-	1	12.5	8	100.0
C12-13	Hypopharynx	53	73.6	10	13.9	9	12.5	-	-	-	-	-	-	72	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	71	64.5	29	26.4	10	9.1	-	-	-	-	-	-	110	100.0
C16	Stomach	114	60.0	63	33.2	11	5.8	-	-	-	-	2	1.1	190	100.0
C17	Small Intestine	8	72.7	3	27.3	-	-	-	-	-	-	-	-	11	100.0
C18	Colon	69	57.5	40	33.3	9	7.5	-	-	-	-	2	1.7	120	100.0
C19-20	Rectum	89	54.3	59	36.0	12	7.3	-	-	-	-	4	2.4	164	100.0
C21	Anus & Anal Canal	2	40.0	2	40.0	1	20.0	-	-	-	-	-	-	5	100.0
C22	Liver	138	74.6	34	18.4	10	5.4	-	-	-	-	3	1.6	185	100.0
C23-24	Gallbladder etc.	15	45.5	14	42.4	4	12.1	-	-	-	-	-	-	33	100.0
C25	Pancreas	31	59.6	14	26.9	6	11.5	-	-	-	-	1	1.9	52	100.0
C30-31	Nose, Sinuses etc.	5	62.5	3	37.5	-	-	-	-	-	-	-	-	8	100.0
C32	Larynx	82	64.6	29	22.8	15	11.8	1	0.8	-	-	-	-	127	100.0
C33-34	Lung etc.	260	48.8	204	38.3	63	11.8	-	-	-	-	6	1.1	533	100.0
C37-38	Other Thoracic Organs	7	63.6	3	27.3	1	9.1	-	-	-	-	-	-	11	100.0
C40-41	Bone	14	53.8	7	26.9	3	11.5	-	-	-	-	2	7.7	26	100.0
C43	Melanoma of Skin	10	71.4	2	14.3	1	7.1	-	-	-	-	1	7.1	14	100.0
C44	Other Skin	30	71.4	8	19.0	4	9.5	-	-	-	-	-	-	42	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	22	47.8	19	41.3	5	10.9	-	-	-	-	-	-	46	100.0
C50	Breast	3	60.0	1	20.0	1	20.0	-	-	-	-	-	-	5	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	7	100.0	-	-	-	-	-	-	-	-	-	-	7	100.0
C61	Prostate	73	52.9	46	33.3	19	13.8	-	-	-	-	-	-	138	100.0
C62	Testis	3	75.0	1	25.0	-	-	-	-	-	-	-	-	4	100.0
C63	Other Male Genital	1	100.0	-	-	-	-	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	31	55.4	22	39.3	2	3.6	-	-	-	-	1	1.8	56	100.0
C65	Renal Pelvis	1	50.0	1	50.0	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	4	80.0	1	20.0	-	-	-	-	-	-	-	-	5	100.0
C67	Bladder	51	56.0	35	38.5	5	5.5	-	-	-	-	-	-	91	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	12.5	4	50.0	3	37.5	-	-	-	-	-	-	8	100.0
C70-72	Brain, Nervous System	26	43.3	28	46.7	5	8.3	-	-	-	-	1	1.7	60	100.0
C73	Thyroid	40	51.9	28	36.4	9	11.7	-	-	-	-	-	-	77	100.0
C74	Adrenal Gland	2	66.7	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	8	47.1	8	47.1	1	5.9	-	-	-	-	-	-	17	100.0
C82-85,C96	NHL	95	58.6	54	33.3	12	7.4	-	-	-	-	1	0.6	162	100.0
C88	Malig Imm.Prol D	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	51	61.4	23	27.7	8	9.6	-	-	-	-	1	1.2	83	100.0
C91	Lymphoid Leuk.	26	41.3	32	50.8	5	7.9	-	-	-	-	-	-	63	100.0
C92-94	Myeloid Leukaemia	39	50.6	31	40.3	7	9.1	-	-	-	-	-	-	77	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	35	53.8	23	35.4	6	9.2	-	-	-	-	1	1.5	65	100.0
	All Sites	1842	58.8	967	30.9	291	9.3	1	0.0	-	-	29	0.9	3130	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



**Hospital Based Cancer Registry
524 HBCR - Malabar Cancer Centre, Kannur**

Report Based on Year of Registration : 2022

TABLE 12(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion - Females

As on: 23/05/2024

ICD 10	Site	Hindu		Muslim		Christian		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	6	85.7	1	14.3	-	-	-	-	-	-	7	100.0
C01-02	Tongue	32	61.5	17	32.7	3	5.8	-	-	-	-	52	100.0
C03-06	Mouth	57	67.9	21	25.0	6	7.1	-	-	-	-	84	100.0
C07-08	Salivary Gland	5	41.7	4	33.3	3	25.0	-	-	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	6	100.0	-	-	-	-	-	-	-	-	6	100.0
C11	Nasopharynx	2	28.6	5	71.4	-	-	-	-	-	-	7	100.0
C12-13	Hypopharynx	12	66.7	6	33.3	-	-	-	-	-	-	18	100.0
C14	Pharynx Unspecified	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C15	Oesophagus	34	73.9	9	19.6	-	-	-	-	3	6.5	46	100.0
C16	Stomach	45	64.3	20	28.6	5	7.1	-	-	-	-	70	100.0
C17	Small Intestine	7	50.0	7	50.0	-	-	-	-	-	-	14	100.0
C18	Colon	64	56.1	45	39.5	4	3.5	-	-	1	0.9	114	100.0
C19-20	Rectum	75	59.1	42	33.1	6	4.7	-	-	4	3.1	127	100.0
C21	Anus & Anal Canal	5	100.0	-	-	-	-	-	-	-	-	5	100.0
C22	Liver	33	54.1	24	39.3	4	6.6	-	-	-	-	61	100.0
C23-24	Gallbladder etc.	13	50.0	13	50.0	-	-	-	-	-	-	26	100.0
C25	Pancreas	22	57.9	14	36.8	2	5.3	-	-	-	-	38	100.0
C30-31	Nose, Sinuses etc.	3	42.9	3	42.9	1	14.3	-	-	-	-	7	100.0
C32	Larynx	8	66.7	3	25.0	-	-	-	-	1	8.3	12	100.0
C33-34	Lung etc.	77	63.6	34	28.1	8	6.6	-	-	2	1.7	121	100.0
C37-38	Other Thoracic Organs	1	50.0	-	-	-	-	-	-	1	50.0	2	100.0
C40-41	Bone	11	64.7	4	23.5	2	11.8	-	-	-	-	17	100.0
C43	Melanoma of Skin	6	50.0	6	50.0	-	-	-	-	-	-	12	100.0
C44	Other Skin	18	62.1	10	34.5	1	3.4	-	-	-	-	29	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	22	62.9	13	37.1	-	-	-	-	-	-	35	100.0
C50	Breast	532	62.1	252	29.4	67	7.8	-	-	5	0.6	856	100.0
C51	Vulva	2	100.0	-	-	-	-	-	-	-	-	2	100.0
C52	Vagina	8	100.0	-	-	-	-	-	-	-	-	8	100.0
C53	Cervix Uteri	125	73.1	33	19.3	12	7.0	-	-	1	0.6	171	100.0
C54	Corpus Uteri	111	65.3	40	23.5	17	10.0	-	-	2	1.2	170	100.0
C55	Uterus Unspecified	6	60.0	2	20.0	1	10.0	-	-	1	10.0	10	100.0
C56	Ovary etc.	104	60.8	52	30.4	14	8.2	-	-	1	0.6	171	100.0
C57	Other Female Genital	1	50.0	1	50.0	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	7	43.8	8	50.0	-	-	-	-	1	6.2	16	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	9	64.3	4	28.6	1	7.1	-	-	-	-	14	100.0
C68	Uns. Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	-	-	4	100.0	-	-	-	-	-	-	4	100.0
C70-72	Brain, Nervous System	25	80.6	3	9.7	3	9.7	-	-	-	-	31	100.0
C73	Thyroid	161	63.6	71	28.1	18	7.1	-	-	3	1.2	253	100.0
C74	Adrenal Gland	1	33.3	2	66.7	-	-	-	-	-	-	3	100.0
C81	Hodgkins Disease	3	33.3	5	55.6	1	11.1	-	-	-	-	9	100.0
C82-85,C96	NHL	65	59.6	36	33.0	7	6.4	-	-	1	0.9	109	100.0
C88	Malig Imm. Prol D	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	33	78.6	5	11.9	3	7.1	-	-	1	2.4	42	100.0
C91	Lymphoid Leuk.	23	65.7	12	34.3	-	-	-	-	-	-	35	100.0
C92-94	Myeloid Leukaemia	31	54.4	22	38.6	4	7.0	-	-	-	-	57	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	22	52.4	16	38.1	3	7.1	-	-	1	2.4	42	100.0
	All Sites	1834	62.6	870	29.7	196	6.7	-	-	29	1.0	2929	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 13(a): Number(#) and Proportion(%) of cancers by site (ICD-10) and Education - Males

As on: 23/05/2024

ICD 10	Site	Middle		Primary		Secondary		Literate		Illiterate		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	1	16.7	1	16.7	2	33.3	2	33.3	-	-	-	-	-	-	6	100.0
C01-02	Tongue	50	40.0	20	16.0	22	17.6	12	9.6	12	9.6	9	7.2	-	-	125	100.0
C03-06	Mouth	74	39.2	41	21.7	24	12.7	23	12.2	21	11.1	6	3.2	-	-	189	100.0
C07-08	Salivary Gland	5	25.0	2	10.0	6	30.0	2	10.0	2	10.0	3	15.0	-	-	20	100.0
C09	Tonsil	2	66.7	-	-	1	33.3	-	-	-	-	-	-	-	-	3	100.0
C10	Oth. Oropharynx	48	45.7	17	16.2	12	11.4	10	9.5	13	12.4	5	4.8	-	-	105	100.0
C11	Nasopharynx	2	25.0	2	25.0	3	37.5	-	-	-	-	1	12.5	-	-	8	100.0
C12-13	Hypopharynx	26	36.1	19	26.4	6	8.3	11	15.3	8	11.1	1	1.4	1	1.4	72	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C15	Oesophagus	43	39.1	31	28.2	8	7.3	14	12.7	12	10.9	2	1.8	-	-	110	100.0
C16	Stomach	75	39.5	36	18.9	32	16.8	18	9.5	22	11.6	7	3.7	-	-	190	100.0
C17	Small Intestine	3	27.3	1	9.1	3	27.3	1	9.1	2	18.2	1	9.1	-	-	11	100.0
C18	Colon	39	32.5	25	20.8	22	18.3	11	9.2	12	10.0	10	8.3	1	0.8	120	100.0
C19-20	Rectum	64	39.0	39	23.8	21	12.8	17	10.4	14	8.5	8	4.9	1	0.6	164	100.0
C21	Anus & Anal Canal	3	60.0	1	20.0	-	-	-	-	-	-	1	20.0	-	-	5	100.0
C22	Liver	68	36.8	38	20.5	33	17.8	19	10.3	14	7.6	13	7.0	-	-	185	100.0
C23-24	Gallbladder etc.	15	45.5	3	9.1	7	21.2	2	6.1	4	12.1	2	6.1	-	-	33	100.0
C25	Pancreas	24	46.2	6	11.5	9	17.3	7	13.5	1	1.9	5	9.6	-	-	52	100.0
C30-31	Nose, Sinuses etc.	2	25.0	2	25.0	1	12.5	3	37.5	-	-	-	-	-	-	8	100.0
C32	Larynx	53	41.7	21	16.5	22	17.3	15	11.8	12	9.4	4	3.1	-	-	127	100.0
C33-34	Lung etc.	175	32.8	158	29.6	55	10.3	73	13.7	59	11.1	9	1.7	4	0.8	533	100.0
C37-38	Other Thoracic Organs	4	36.4	1	9.1	3	27.3	2	18.2	-	-	1	9.1	-	-	11	100.0
C40-41	Bone	4	15.4	1	3.8	13	50.0	3	11.5	-	-	5	19.2	-	-	26	100.0
C43	Melanoma of Skin	7	50.0	3	21.4	1	7.1	2	14.3	1	7.1	-	-	-	-	14	100.0
C44	Other Skin	20	47.6	7	16.7	2	4.8	6	14.3	4	9.5	3	7.1	-	-	42	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	18	39.1	6	13.0	11	23.9	4	8.7	1	2.2	6	13.0	-	-	46	100.0
C50	Breast	3	60.0	2	40.0	-	-	-	-	-	-	-	-	-	-	5	100.0
C51	Vulva	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C52	Vagina	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C53	Cervix Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C54	Corpus Uteri	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C55	Uterus Unspecified	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C56	Ovary etc.	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C57	Other Female Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C58	Placenta	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C60	Penis	3	42.9	2	28.6	1	14.3	-	-	1	14.3	-	-	-	-	7	100.0
C61	Prostate	51	37.0	25	18.1	28	20.3	12	8.7	13	9.4	9	6.5	-	-	138	100.0
C62	Testis	1	25.0	-	-	2	50.0	-	-	-	-	1	25.0	-	-	4	100.0
C63	Other Male Genital	-	-	-	-	-	-	1	100.0	-	-	-	-	-	-	1	100.0
C64	Kidney etc.	17	30.4	5	8.9	15	26.8	5	8.9	6	10.7	8	14.3	-	-	56	100.0
C65	Renal Pelvis	2	100.0	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C66	Ureter	3	60.0	-	-	1	20.0	-	-	1	20.0	-	-	-	-	5	100.0
C67	Bladder	31	34.1	28	30.8	9	9.9	13	14.3	9	9.9	1	1.1	-	-	91	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	12.5	-	-	-	-	-	-	-	-	6	75.0	1	12.5	8	100.0
C70-72	Brain, Nervous System	15	25.0	4	6.7	19	31.7	5	8.3	6	10.0	11	18.3	-	-	60	100.0
C73	Thyroid	26	33.8	12	15.6	19	24.7	6	7.8	3	3.9	11	14.3	-	-	77	100.0
C74	Adrenal Gland	-	-	2	66.7	-	-	-	-	-	-	1	33.3	-	-	3	100.0
C81	Hodgkins Disease	3	17.6	1	5.9	5	29.4	2	11.8	1	5.9	4	23.5	1	5.9	17	100.0
C82-85,C96	NHL	55	34.0	23	14.2	33	20.4	14	8.6	12	7.4	25	15.4	-	-	162	100.0
C88	Malig Imm.Prol D	1	100.0	-	-	-	-	-	-	-	-	-	-	-	-	1	100.0
C90	Multiple Myeloma	40	48.2	15	18.1	13	15.7	7	8.4	2	2.4	6	7.2	-	-	83	100.0
C91	Lymphoid Leuk.	14	22.2	10	15.9	11	17.5	3	4.8	5	7.9	20	31.7	-	-	63	100.0
C92-94	Myeloid Leukaemia	25	32.5	10	13.0	16	20.8	7	9.1	1	1.3	17	22.1	1	1.3	77	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	29	44.6	11	16.9	8	12.3	7	10.8	6	9.2	3	4.6	1	1.5	65	100.0
	All Sites	1145	36.6	631	20.2	499	15.9	339	10.8	280	8.9	225	7.2	11	0.4	3130	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH
NATIONAL CANCER REGISTRY PROGRAMME**

(Indian Council of Medical Research)



Hospital Based Cancer Registry

524 HBCR - Malabar Cancer Centre, Kannur

Report Based on Year of Registration : 2022

TABLE 13(b): Number(#) and Proportion(%) of cancers by site (ICD-10) and Education - Females

As on: 23/05/2024

ICD 10	Site	Middle		Primary		Secondary		Literate		Illiterate		Others		Unknown		Total	
		#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%
C00	Lip	2	28.6	2	28.6	1	14.3	-	-	2	28.6	-	-	-	-	7	100.0
C01-02	Tongue	13	25.0	12	23.1	2	3.8	8	15.4	14	26.9	3	5.8	-	-	52	100.0
C03-06	Mouth	22	26.2	12	14.3	2	2.4	16	19.0	31	36.9	-	-	1	1.2	84	100.0
C07-08	Salivary Gland	6	50.0	-	-	3	25.0	-	-	1	8.3	2	16.7	-	-	12	100.0
C09	Tonsil	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C10	Oth. Oropharynx	3	50.0	-	-	1	16.7	-	-	-	-	2	33.3	-	-	6	100.0
C11	Nasopharynx	1	14.3	2	28.6	1	14.3	2	28.6	1	14.3	-	-	-	-	7	100.0
C12-13	Hypopharynx	5	27.8	4	22.2	2	11.1	3	16.7	4	22.2	-	-	-	-	18	100.0
C14	Pharynx Unspecified	-	-	-	-	-	-	-	-	-	-	1	100.0	-	-	1	100.0
C15	Oesophagus	20	43.5	10	21.7	-	-	4	8.7	12	26.1	-	-	-	-	46	100.0
C16	Stomach	24	34.3	13	18.6	9	12.9	7	10.0	14	20.0	3	4.3	-	-	70	100.0
C17	Small Intestine	5	35.7	5	35.7	2	14.3	2	14.3	-	-	-	-	-	-	14	100.0
C18	Colon	37	32.5	30	26.3	16	14.0	12	10.5	9	7.9	10	8.8	-	-	114	100.0
C19-20	Rectum	44	34.6	33	26.0	15	11.8	11	8.7	20	15.7	4	3.1	-	-	127	100.0
C21	Anus & Anal Canal	2	40.0	1	20.0	1	20.0	-	-	1	20.0	-	-	-	-	5	100.0
C22	Liver	19	31.1	16	26.2	6	9.8	10	16.4	8	13.1	2	3.3	-	-	61	100.0
C23-24	Gallbladder etc.	11	42.3	7	26.9	3	11.5	1	3.8	4	15.4	-	-	-	-	26	100.0
C25	Pancreas	16	42.1	7	18.4	2	5.3	5	13.2	5	13.2	2	5.3	1	2.6	38	100.0
C30-31	Nose, Sinuses etc.	2	28.6	2	28.6	-	-	2	28.6	-	-	1	14.3	-	-	7	100.0
C32	Larynx	4	33.3	3	25.0	-	-	2	16.7	1	8.3	2	16.7	-	-	12	100.0
C33-34	Lung etc.	37	30.6	34	28.1	9	7.4	15	12.4	17	14.0	7	5.8	2	1.7	121	100.0
C37-38	Other Thoracic Organs	2	100.0	-	-	-	-	-	-	-	-	-	-	-	-	2	100.0
C40-41	Bone	6	35.3	1	5.9	2	11.8	3	17.6	1	5.9	3	17.6	1	5.9	17	100.0
C43	Melanoma of Skin	2	16.7	5	41.7	4	33.3	1	8.3	-	-	-	-	-	-	12	100.0
C44	Other Skin	13	44.8	7	24.1	4	13.8	2	6.9	2	6.9	1	3.4	-	-	29	100.0
C45	Mesothelioma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C46	Kaposi Sarcoma	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C47+C49	Conn. & Soft Tissue	12	34.3	7	20.0	3	8.6	4	11.4	2	5.7	6	17.1	1	2.9	35	100.0
C50	Breast	319	37.3	121	14.1	159	18.6	108	12.6	59	6.9	90	10.5	-	-	856	100.0
C51	Vulva	1	50.0	-	-	-	-	1	50.0	-	-	-	-	-	-	2	100.0
C52	Vagina	6	75.0	-	-	-	-	1	12.5	1	12.5	-	-	-	-	8	100.0
C53	Cervix Uteri	64	37.4	29	17.0	21	12.3	23	13.5	30	17.5	3	1.8	1	0.6	171	100.0
C54	Corpus Uteri	73	42.9	31	18.2	22	12.9	16	9.4	15	8.8	13	7.6	-	-	170	100.0
C55	Uterus Unspecified	2	20.0	3	30.0	3	30.0	1	10.0	-	-	1	10.0	-	-	10	100.0
C56	Ovary etc.	57	33.3	33	19.3	17	9.9	19	11.1	27	15.8	18	10.5	-	-	171	100.0
C57	Other Female Genital	1	50.0	1	50.0	-	-	-	-	-	-	-	-	-	-	2	100.0
C58	Placenta	-	-	-	-	1	100.0	-	-	-	-	-	-	-	-	1	100.0
C60	Penis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Testis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Other Male Genital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Kidney etc.	5	31.2	4	25.0	2	12.5	4	25.0	-	-	1	6.2	-	-	16	100.0
C65	Renal Pelvis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C66	Ureter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C67	Bladder	5	35.7	4	28.6	2	14.3	1	7.1	2	14.3	-	-	-	-	14	100.0
C68	Uns.Urinary Organs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C69	Eye	1	25.0	-	-	-	-	-	-	-	-	3	75.0	-	-	4	100.0
C70-72	Brain, Nervous System	17	54.8	5	16.1	4	12.9	2	6.5	1	3.2	2	6.5	-	-	31	100.0
C73	Thyroid	86	34.0	32	12.6	67	26.5	21	8.3	9	3.6	38	15.0	-	-	253	100.0
C74	Adrenal Gland	2	66.7	-	-	-	-	-	-	-	-	1	33.3	-	-	3	100.0
C81	Hodgkins Disease	2	22.2	-	-	-	-	1	11.1	1	11.1	5	55.6	-	-	9	100.0
C82-85,C96	NHL	44	40.4	11	10.1	17	15.6	8	7.3	17	15.6	12	11.0	-	-	109	100.0
C88	Malig Imm.Prol D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C90	Multiple Myeloma	14	33.3	10	23.8	6	14.3	5	11.9	6	14.3	1	2.4	-	-	42	100.0
C91	Lymphoid Leuk.	9	25.7	4	11.4	8	22.9	2	5.7	2	5.7	10	28.6	-	-	35	100.0
C92-94	Myeloid Leukaemia	14	24.6	10	17.5	18	31.6	5	8.8	4	7.0	6	10.5	-	-	57	100.0
C95	Leukaemia Uns	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
O&U	Other and Uns	13	31.0	13	31.0	6	14.3	1	2.4	3	7.1	6	14.3	-	-	42	100.0
	All Sites	1043	35.6	524	17.9	441	15.1	329	11.2	326	11.1	259	8.8	7	0.2	2929	100.0

O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97

**DETAILED
INFORMATION-MCC**

Table 1: Number of New and Old Cancer Cases

Sex	New	%	Old	%	Total
Female	1900	64.9%	1029	35.1%	2929
Male	2274	72.7%	856	27.3%	3130

Table 2: Number and Proportion of System wise & Sex wise Cancer Incidence

System	Male	%	Female	%	Total
Digestive Organs	890	63.5%	511	36.5%	1401
Head & Neck	665	76.3%	207	23.7%	872
Breast	4	0.5%	857	99.5%	861
Respiratory system	557	80.6%	134	19.4%	691
Hematopoietic&reticuloendothelial system	366	61.1%	233	38.9%	599
Female genital system			535	100.0%	535
Endocrine glands	82	24.3%	256	75.7%	338
Urinary tract	154	83.7%	30	16.3%	184
Male genital organ	150	100.0%			150
Eye & CNS	68	65.4%	36	34.6%	104
Skin	55	56.7%	42	43.3%	97
Primary unknown	58	61.4%	35	37.6%	93
Soft tissue system	42	58.3%	30	41.7%	72
skeletal-bones etc	35	66.0%	18	34.0%	53
Peripheral nervous system	4	44.4%	5	55.6%	9
Total	3130	52%	2929	48%	6059

Table 3: Number (#) and Proportion of System wise habits and family history

System	Smoking	%	Alcohol	%	Pan chewing	%	Family History	%	Total
Digestive Organs	238	17.0%	220	15.7%	164	11.7%	367	26.2%	1401
Head & Neck	286	32.8%	261	29.9%	248	28.4%	168	19.3%	872
Breast	18	2.1%	17	2.0%	37	4.3%	288	33.4%	861
Respiratory system	246	35.6%	127	18.4%	93	13.5%	103	14.9%	691
Hematopoietic&reticuloendothelial system	57	9.5%	51	8.5%	39	6.5%	76	12.7%	599
Female genital system	6	1.1%	9	1.7%	40	7.5%	147	27.5%	535
Endocrine glands	15	4.4%	18	5.3%	13	3.8%	66	19.5%	338
Urinary tract	32	17.4%	18	9.8%	16	8.7%	55	29.9%	184
Male genital organ	25	16.7%	23	15.3%	20	13.3%	32	21.3%	150
Eye & CNS	7	6.7%	6	5.8%	1	1.0%	8	7.7%	104
Skin	14	14.4%	13	13.4%	12	12.4%	21	21.6%	97
Primary unknown	25	26.9%	18	19.4%	12	12.9%	15	16.1%	93
Soft tissue system	3	4.2%	6	8.3%	7	9.7%	29	40.3%	72
skeletal-bones etc	4	7.5%	3	5.7%	0	0.0%	8	15.1%	53
Peripheral nervous system	0	0.0%	0	0.0%	0	0.0%	2	22.2%	9

Family History/ Hereditary Cancer

Table 4: Numbers (#) and Proportion of Family History with Hereditary Cancers

Site	No. of Patients	%	Total
Breast	288	33.4%	861
Rectum	83	28.5%	291
Colon	69	29.5%	234
Ovary	41	24.0%	171
Prostate	32	23.2%	138

Ten Leading Cancers - irrespective of Sex

Table 5 : Numbers (#) and Proportion of leading site of cancers- irrespective of sex

Leading site	Male	%	Female	%	Total
Breast	4	0.5%	857	99.5%	861
Lung	533	81.5%	121	18.5%	654
Thyroid	77	23.3%	253	76.7%	330
Rectum	164	56.4%	127	43.6%	291
Mouth	189	69.2%	84	30.8%	273
NHL	162	59.8%	109	40.2%	271
Stomach	190	73.1%	70	26.9%	260
Liver	185	75.2%	61	24.8%	246
Colon	120	51.3%	114	48.7%	234
Tongue	125	70.6%	52	29.4%	177

I Breast Cancer

- Total Number (ICD 10: C50) : 861
- Breast cancer is the first leading cancer among females
- Ist leading cancer among females: 29.2 %
- Peak age group: 45-49 years in females
- Histology: Infiltrating Ductal Carcinoma: 87.5%in females
- Method of diagnosis: Microscopic : 98.8%in females
- Detailed Microscopic diagnosis: Histology of Primary: 97.4%in females
- Broad treatment group: Treatment only at RI: 51.1 % in females
- Clinical extent of disease before treatment (Treatment only at RI): Direct extension with regional nodes : 42.9% in females
- Intention to treat(treatment only at RI) : Curative/Radical(Treatment only at RI): 86.5 % in females
- Composite stage : Stage 2: 46.2% in females.

Table 6: Number and Relative Proportion of Breast cancer by five year age group

Breast					
Age	Male	%	Female	%	Total
20-24	0	0.0%	1	0.1%	1
25-29	0	0.0%	5	0.6%	5
30-34	0	0.0%	20	2.3%	20
35-39	0	0.0%	50	5.8%	50
40-44	0	0.0%	98	11.4%	98
45-49	0	0.0%	144	16.8%	144
50-54	0	0.0%	136	15.9%	136
55-59	0	0.0%	117	13.7%	117
60-64	2	50.0%	108	12.6%	110
65-69	1	25.0%	90	10.5%	91
70-74	1	25.0%	56	6.5%	57
>=75	0	0.0%	32	3.7%	32
Total	4	100%	857	100%	861

Table 7: Number and Relative Proportion of Breast cancer by Broad treatment group

Breast					
Broad treatment group	Male	%	Female	%	Total
No treatment	0	0.0%	58	6.8%	58
Others	0	0.0%	104	12.1%	104
Prior & Treatment at RI	3	75.0%	173	20.2%	176
Prior Treatment Only	0	0.0%	84	9.8%	84
Treatment only at RI	1	25.0%	438	51.1%	439
Total	4	100%	857	100%	861

Table 8: Number and Relative Proportion of Breast cancer by Clinical extent of disease (Treatment only at RI)

Breast					
Clinical Extent before Treatment	Male	%	Female	%	Total
Direct Extension	0	0.0%	8	1.8%	8
Direct Extension with Regional Nodes	0	0.0%	188	42.9%	188
Distant Metastasis	0	0.0%	63	14.4%	63
Localised	1	100.0%	175	40.0%	176
Too Advanced	0	0.0%	4	0.9%	4
Total	1	100%	438	100%	439

Table 9: Number and Relative Proportion of Breast cancer by Composite stage

Breast					
Composite stage	Male	%	Female	%	Total
stage1	0	0.0%	61	7.1%	61
stage2	3	75.0%	396	46.2%	399
stage3	0	0.0%	196	22.9%	196
stage4	1	25.0%	163	19.0%	164
Unknown	0	0.0%	41	4.8%	41
Total	4	100%	857	100%	861

Table 10: Number and Relative Proportion of Breast cancer by intention to treat (Treatment Only at RI)

Breast					
Curative / Radical	1	100.0%	379	86.5%	380
Palliative	0	0.0%	58	13.2%	58
Symptomatic	0	0.0%	1	0.2%	1
Total	1	100%	438	100%	439

Table 11: Number and Relative Proportion of Breast cancer by Diagnostic status

Breast						
Diagnostic status	Male	%	Female	%	Total	
Microscopically Confirmed	4	100.0%	847	98.8%	851	
No registered at RI	0	0.0%	2	0.2%	2	
Suspected (Clinically / To rule out Malignancy)	0	0.0%	2	0.2%	2	
Suspected (Microscopically / Radiologically)	0	0.0%	6	0.7%	6	
Total	4	100%	857	100%	861	

Table 12: Number and Relative Proportion of Breast cancer by Detailed Microscopic Diagnosis

Breast					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	0	0.0%	1	0.1%	1
Cytology of Primary	0	0.0%	15	1.8%	15
Histology of Metastasis	0	0.0%	6	0.7%	6
Histology of Primary	4	100.0%	825	97.4%	829
Total	4	100%	847	100%	851

Table 13: Number and Relative Proportion of Breast cancer by Morphology

Broad Histological Classification - Breast(ICD10: C50)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Females		
	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	11	1.3	1.3
Carcinoma (8010-8035)	40	4.7	4.7
Papillary Carcinoma (8050,8260)	5	0.6	0.6
Mucinous Adeno Carcinoma (8430,8480-8482,8490)	9	1.1	1.0
Infiltrating Duct Carcinoma (8500-8508,8521,8523)	752	88.6	87.5
Lobular Carcinoma (8520,8522,8524)	18	2.1	2.1
Paget's Disease (8540-8543)	1	0.1	0.1
Others	13	1.5	1.5
All Microscopic	849	100.0	98.8
Non Microscopic	10	-	1.2
Total	859	-	100.0
* All Microscopic ** Total			

II Lung Cancer

- Total Number (ICD 10: C33-34) :654 (18.5% females and 81.5% males)
- Lung cancer is the first leading cancer among males
- Ist leading cancer among males : 17% and 7th leading cancer in females : 4.1%
- Peak age group: 65-69 years in males and 60-64 in females
- Histology: Adenocarcinoma: 24.6 % in males and 50.4% in females
- Method of diagnosis: Microscopic : 90.1 % in females and 82% in males
- Detailed Microscopic diagnosis: Histology of Primary: 74.3% in females and 76.9% in males.
- Broad treatment group: Treatment only at RI: 38% in females and 37.9% in males
- Clinical extent of disease before treatment(Treatment only at RI) : Distant metastasis: 84.8% in females and 60.4% in males
- Intention to treat (Treatment only at RI) : Palliative: 93.5% in females and 86.6% in males
- Composite stage: Stage 4: 68.7 % in males and 79.3 % in females

Table 14 :Number and Relative Proportion of Lung cancer by five year age group

Lung					
Age	Male	%	Female	%	Total
20-24	0	0.0%	1	0.8%	1
25-29	1	0.2%	0	0.0%	1
30-34	1	0.2%	0	0.0%	1
35-39	0	0.0%	2	1.7%	2
40-44	7	1.3%	6	5.0%	13
45-49	10	1.9%	8	6.6%	18
50-54	26	4.9%	11	9.1%	37
55-59	43	8.1%	19	15.7%	62
60-64	123	23.1%	24	19.8%	147
65-69	131	24.6%	15	12.4%	146
70-74	116	21.8%	20	16.5%	136
>=75	75	14.1%	15	12.4%	90
Total	533	100%	121	100%	654

Table 15 : Number and Relative Proportion of Lung cancer by Broad Treatment Groups

Lung					
Broad treatment group	Male	%	Female	%	Total
No treatment	194	36.4%	43	35.5%	237
others	75	14.1%	14	11.6%	89
Prior & Treatment at RI	31	5.8%	8	6.6%	39
Prior Treatment Only	31	5.8%	10	8.3%	41
Treatment only at RI	202	37.9%	46	38.0%	248
Total	533	100%	121	100%	654

Table 16: Number and Relative Proportion of Lung cancer by Clinical Extent of Disease (Treatment only at RI)

Lung					
Clinical Extent before treatment	Male	%	Female	%	Total
Direct Extension	5	2.5%	1	2.2%	6
Direct Extension with Regional Nodes	61	30.2%	4	8.7%	65
Distant Metastasis	122	60.4%	39	84.8%	161
Localised	7	3.5%	1	2.2%	8
Too Advanced	7	3.5%	1	2.2%	8
Total	202	100%	46	100%	248

Table 17: Number and Relative Proportion of Lung cancer by histology

Broad Histological Classification - Lung(ICD10: C33-34)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	115	26.4	21.6	32	29.4	26.4
Large Cell Carcinoma (8012,8013,8014)	1	0.2	0.2	-	-	-
Small Cell Carc. (8041,8043,8044,8045)	51	11.7	9.6	5	4.6	4.1
Squamous Cell Carcinoma (8070-8078,8084)	116	26.6	21.8	5	4.6	4.1
Other Carcinomas (8010,8032,8033,8034,8040 ,8042,8430,8440,84, 80)	8	1.8	1.5	5	4.6	4.1
Adeno Carcinoma (8140, 8141, 8200, 8210, 8240, 8241, 8246,8250, 8251, 8253, 8254, 8255,8260,8310,8481,8490,8560)	131	30.0	24.6	61	56.0	50.4
Others	14	3.2	2.6	1	0.9	0.8
All Microscopic	436	100.0	81.8	109	100.0	90.1
Non Microscopic	97	-	18.2	12	-	9.9
Total	533	-	100.0	121	-	100.0
* All Microscopic ** Total						

Table 18: Number and Relative Proportion of Lung cancer by Intention to treat (Treatment only at RI)

Lung					
Intention	Male	%	Female	%	Total
Curative / Radical	27	13.4%	3	6.5%	30
Palliative	175	86.6%	43	93.5%	218
Total	202	100%	46	100%	248

Table 19: Number and Relative Proportion of Lung cancer by Composite stage

Lung					
Composite stage	Male	%	Female	%	Total
stage1	9	1.7%	2	1.7%	11
stage2	16	3.0%	6	5.0%	22
stage3	126	23.6%	13	10.7%	139
stage4	366	68.7%	96	79.3%	462
Unknown	16	3.0%	4	3.3%	20
Total	533	100%	121	100%	654

Table 20: Number and Relative Proportion of Lung cancer by Diagnostic status

Lung					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	437	82.0%	109	90.1%	546
Suspected (Microscopically / Radiologically)	96	18.0%	12	9.9%	108
Total	533	100%	121	100%	654

Table 21 : Number and Relative Proportion of Lung cancer by Detailed Microscopic Diagnosis

Lung					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	31	7.1%	10	9.2%	41
Cytology of Primary	30	6.9%	6	5.5%	36
Histology of Metastasis	40	9.2%	12	11.0%	52
Histology of Primary	336	76.9%	81	74.3%	417
Total	437	100%	109	100%	546

III Thyroid

- Total Number (ICD 10: C73) : 330 (76.7% females and 23.3% males)
- 2nd leading cancer among females
- Peak age group: 60-64 years in males and 45-49 in females
- Histology : Papillary adenocarcinoma: 54.5 % in males and 58.9% in females
- Method of diagnosis: Microscopic: 98.7% in males and 100% in females
- Detailed Microscopic diagnosis: Histology of Primary : 86.8% in males and 93.3% in females
- Broad treatment group: Prior & Treatment at RI: 48.1% in males and 48.6 % in females
- Clinical extent of disease before treatment (Treatment only at RI): Localised: 29.4% in males and 60.5% in females
- Intention to treat (treatment only at RI) : Curative/Radical : 76.5% in males and 95.3% in females
- Composite Stage: Stage 4: 36.4 % in males and 26.5 % in females

Table 22: Number and Relative Proportion of Thyroid cancer by Five year age group

Mouth					
Age	Male	%	Female	%	Total
10-14	1	1.3%	4	1.6%	5
15-19	3	3.9%	5	2.0%	8
20-24	4	5.2%	12	4.7%	16
25-29	3	3.9%	8	3.2%	11
30-34	6	7.8%	21	8.3%	27
35-39	4	5.2%	27	10.7%	31
40-44	4	5.2%	37	14.6%	41
45-49	11	14.3%	41	16.2%	52
50-54	6	7.8%	28	11.1%	34
55-59	6	7.8%	17	6.7%	23
60-64	12	15.6%	23	9.1%	35
65-69	8	10.4%	15	5.9%	23
70-74	6	7.8%	10	4.0%	16
>=75	3	3.9%	5	2.0%	8
Total	77	100%	253	100%	330

Table 23: Number and Relative Proportion of Thyroid cancer by Broad Treatment Group

Thyroid					
Broad treatment group	Male	%	Female	%	Total
No treatment	4	5.2%	12	4.7%	16
Others	2	2.6%	12	4.7%	14
Prior & Treatment at RI	37	48.1%	123	48.6%	160
Prior Treatment Only	17	22.1%	63	24.9%	80
Treatment only at RI	17	22.1%	43	17.0%	60
Total	77	100%	253	100%	330

Table 24 : Number and Relative Proportion of Thyroid cancer by Clinical extent of disease before treatment (Treatment only at RI)

Thyroid					
Clinical Extent before treatment	Male	%	Female	%	Total
Direct Extension with Regional Nodes	7	41.2%	14	32.6%	21
Distant Metastasis	5	29.4%	3	7.0%	8
Localised	5	29.4%	26	60.5%	31
Total	17	100%	43	100%	60

Table 25 : Number and Relative Proportion of Thyroid cancer by Composite Stage

Thyroid					
Composite stage	Male	%	Female	%	total
stage1	8	10.4%	60	23.7%	68
stage2	16	20.8%	55	21.7%	71
stage3	11	14.3%	21	8.3%	32
stage4	28	36.4%	67	26.5%	95
Unknown	14	18.2%	50	19.8%	64
Total	77	100%	253	100%	330

Table 26 : Number and Relative Proportion of Thyroid cancer by Intention to treat

Thyroid (Treatment only at RI)					
intention	Male	%	Female	%	count
Curative / Radical	13	76.5%	41	95.3%	54
Palliative	4	23.5%	2	4.7%	6
Total	17	100%	43	100%	60

Table 27 : Number and Relative Proportion of Thyroid cancer by Diagnostic Status

Thyroid					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	76	98.7%	253	100.0%	329
Suspected (Clinically / To rule out Malignancy)	1	1.3%	0	0.0%	1
Total	77	100%	253	100%	330

Table 28: Number and Relative Proportion of Thyroid cancer by Detailed Microscopic Diagnosis

Thyroid					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Primary	9	11.8%	16	6.3%	25
Histology of Metastasis	1	1.3%	1	0.4%	2
Histology of Primary	66	86.8%	236	93.3%	302
Total	76	100%	253	100%	329

Table 29 : Number and Relative Proportion of Thyroid cancer by Morphology

WHO Histological Classification - Thyroid(ICD10: C18)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	1	1.3	1.3	1	0.4	0.4
Other Carcinomas (8010- 8012, 8022, 8030-8035, 8041, 8337)	1	1.3	1.3	6	2.4	2.4
Undifferentiated Carc. (8020,8021)	1	1.3	1.3	5	2.0	2.0
Papillary Carc.NOS (8050)	8	10.5	10.4	20	7.9	7.9
Papillary AdenoCarc. (8260,8341,8344,8350)	42	55.3	54.5	149	58.9	58.9
Follicular Carcinoma (8290,8330-8335)	12	15.8	15.6	53	20.9	20.9
Mixed Papi&FolliCarc. (8340)	3	3.9	3.9	17	6.7	6.7
Medullary carcinoma (8346,8347,8510,8512)	7	9.2	9.1	1	0.4	0.4
Others	1	1.3	1.3	1	0.4	0.4
All Microscopic	76	100.0	98.7	253	100.0	100.0
Non Microscopic	1	-	1.3	-	-	-
Total	77	-	100.0	253	-	100.0
* All Microscopic ** Total						

IV RECTUM

- Total Number (ICD 10: C20) : 291(43.6% females and 56.4% males)
- 5th leading cancer among males and 6th leading cancer in females.
- Peak age group: 60-64 years in males and 65-69 years in females
- Histology : Adenocarcinoma: 82.3% in males and 90.6 % in females
- Method of diagnosis: Microscopic: 97.6 % in males and 96.1% in females
- Detailed Microscopic diagnosis: Histology of Primary: 86.8% in males and 93.3% in females
- Broad treatment group: Treatment only at RI : 45.1% in males and 47.2% in females
- Clinical extent of disease before treatment (Treatment only at RI): Direct extension with regional nodes: 56.8 % in males and 51.7 % in females
- Intention to treat(treatment only at RI) :Curative/Radical : 77% in males and 78.3 % in females
- Composite Stage : Stage 3: 44.5 % in males and 40.2 % in females

Table 30 : Number and Relative Proportion of Rectum cancer by Five year age group

Rectum					
Age	Male	%	Female	%	Total
15-19	1	0.6%	0	0.0%	1
25-29	1	0.6%	0	0.0%	1
30-34	1	0.6%	1	0.8%	2
35-39	2	1.2%	1	0.8%	3
40-44	9	5.5%	7	5.5%	16
45-49	7	4.3%	10	7.9%	17
50-54	18	11.0%	10	7.9%	28
55-59	19	11.6%	18	14.2%	37
60-64	36	22.0%	15	11.8%	51
65-69	27	16.5%	23	18.1%	50
70-74	29	17.7%	21	16.5%	50
>=75	14	8.5%	21	16.5%	35
Total	164	100%	127	100%	291

Table 31: Number and Relative Proportion of Rectum cancer by Broad treatment group

Rectum					
Broad treatment group	Male	%	Female	%	Total
No treatment	23	14.0%	27	21.3%	50
Others	27	16.5%	17	13.4%	44
Prior & Treatment at RI	17	10.4%	12	9.4%	29
Prior Treatment Only	23	14.0%	11	8.7%	34
Treatment only at RI	74	45.1%	60	47.2%	134
Total	164	100%	127	100%	291

Table 32: Number and Relative Proportion of Rectum cancer by Clinical extent of disease before treatment (Treatment only at RI)

Rectum					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	8	10.8%	1	1.7%	9
Direct Extension with Regional Nodes	42	56.8%	31	51.7%	73
Distant Metastasis	14	18.9%	12	20.0%	26
Localised	10	13.5%	15	25.0%	25
Others (specify)	0	0.0%	1	1.7%	1
Total	74	100%	60	100%	134

Table 33 : Number and Relative Proportion of Rectum cancer by Composite stage

Rectum					
Composite stage	Male	%	Female	%	Total
stage1	2	1.2%	11	8.7%	13
stage2	21	12.8%	9	7.1%	30
stage3	73	44.5%	51	40.2%	124
stage4	48	29.3%	40	31.5%	88
Unknown	20	12.2%	16	12.6%	36
Total	164	100%	127	100%	291

Table 34 : Number and Relative Proportion of Rectum cancer by intention to treat

Rectum (Treatment only at RI)					
Intension	Male	%	Female	%	Total
Curative / Radical	57	77.0%	47	78.3%	104
Palliative	17	23.0%	13	21.7%	30
Total	74	100%	60	100%	134

Table 35 : Number and Relative Proportion of Rectum cancer by Diagnostic status

Rectum					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	160	97.6%	122	96.1%	282
No registered at RI	1	0.6%	0	0.0%	1
Suspected (Microscopically / Radiologically)	3	1.8%	5	3.9%	8
Total	164	100%	127	100%	291

Table 36 : Number and Relative Proportion of Rectum cancer by Detailed Microscopic Diagnosis

Rectum					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Primary	9	11.8%	16	6.3%	25
Histology of Metastasis	1	1.3%	1	0.4%	2
Histology of Primary	66	86.8%	236	93.3%	302
Total	76	100%	253	100%	329

Table 37 : Number and Relative Proportion of Rectum cancer by Morphology

WHO Histological Classification - Rectum(ICD10: C19-20)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**			
Adenocarcinoma (8140)	135	84.4	82.3	115	94.3	90.6
Mucinous adenocarcinoma (8480)	11	6.9	6.7	2	1.6	1.6
Signet-ring cell carcinoma (8490)	4	2.5	2.4	1	0.8	0.8
Small cell carcinoma (8041)	1	0.6	0.6	-	-	-
Others	9	5.6	5.5	4	3.3	3.1
All Microscopic	160	100.0	97.6	122	100.0	96.1
Non Microscopic	4	-	2.4	5	-	3.9
Total	164	-	100.0	127	-	100.0
* All Microscopic ** Total						

V. Mouth

- Total Number (ICD 10: C03-06) : 273(30.8% females and 69.2% males)
- 3rd leading cancer among males (6%)
- 10th leading cancer among females (2.9%)
- Peak age group: 60-64 years in males and 65-69 years in females.
- Histology : Squamous cell carcinoma : 82.1% in females and 86.2% in males
- Method of diagnosis: Microscopic: 92.9% in females and 95.8% in males
- Detailed Microscopic diagnosis: Histology of Primary: 97.8 % in males and 96.2% in females.
- Broad treatment group: Treatment Only at RI: 65.5% in females and 58.7% in males
- Clinical extent of disease before treatment (Treatment only at RI): Direct extension with regional nodes :38.2 % in females and 43.2 % in males
- Intention to treat (treatment only at RI) : Curative/Radical: 40% in females and 69.4% in males
- Composite stage : Stage 4 : 54% in males and 50% in females

Table 38: Number and Relative Proportion of Mouth cancer by five year age group

Mouth					
Age	Male	%	Female	%	Total
30-34	4	2.1%	3	3.6%	7
35-39	10	5.3%	0	0.0%	10
40-44	13	6.9%	3	3.6%	16
45-49	12	6.3%	6	7.1%	18
50-54	20	10.6%	4	4.8%	24
55-59	23	12.2%	6	7.1%	29
60-64	29	15.3%	10	11.9%	39
65-69	27	14.3%	13	15.5%	40
70-74	25	13.2%	8	9.5%	33
>=75	26	13.8%	31	36.9%	57
Total	189	100%	84	100%	273

Table 39: Number and Relative Proportion of Mouth cancer by Broad treatment group

Mouth					
Broad treatment group	Male	%	Female	%	Total
No treatment	23	12.2%	10	11.9%	33
Others	17	9.0%	11	13.1%	28
Prior & Treatment at RI	18	9.5%	4	4.8%	22
Prior Treatment Only	20	10.6%	4	4.8%	24
Treatment only at RI	111	58.7%	55	65.5%	166
Total	189	100%	84	100%	273

Table 40: Number and Relative Proportion of Mouth cancer by Clinical Extent of Disease (Treatment only at RI)

Mouth					
Clinical Extent before treatment	Male	%	Female	%	Total
Direct Extension	14	12.6%	9	16.4%	23
Direct Extension with Regional Nodes	48	43.2%	21	38.2%	69
Distant Metastasis	2	1.8%	0	0.0%	2
Localised	33	29.7%	20	36.4%	53
Recurrent	1	0.9%	0	0.0%	1
Regional Nodes	2	1.8%	0	0.0%	2
Too Advanced	11	9.9%	5	9.1%	16
Total	111	100%	55	100%	166

Table 41: Number and Relative Proportion of Mouth cancer by Composite stage

Mouth					
Composite stage	Male	%	Female	%	Total
stage1	13	6.9%	7	8.3%	20
stage2	21	11.1%	12	14.3%	33
stage3	40	21.2%	22	26.2%	62
stage4	102	54.0%	42	50.0%	144
Unknown	13	6.9%	1	1.2%	14
Total	189	100%	84	100%	273

Table 42 : Number and Relative Proportion of Mouth cancer by intention to treat

Mouth (Treatment only at RI)					
Intention	Male	%	Female	%	Total
Curative / Radical	77	69.4%	22	40.0%	99
Palliative	34	30.6%	33	60.0%	67
Total	111	100%	55	100%	166

Table 43: Number and Relative Proportion of Mouth cancer by Diagnostic status

Mouth						
Diagnostic status	Male	%	Female	%	Total	
Microscopically Confirmed	181	95.8%	78	92.9%	259	
No registered at RI	1	0.5%	1	1.2%	2	
Suspected (Clinically / To rule out Malignancy)	4	2.1%	4	4.8%	8	
Suspected (Microscopically / Radiologically)	3	1.6%	1	1.2%	4	
Total	189	100%	84	100%	273	

Table 44 : Number and Relative Proportion of Mouth cancer by detailed microscopic diagnosis

Mouth					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.6%	1	1.3%	2
Cytology of Primary	2	1.1%	1	1.3%	3
Histology of Metastasis	1	0.6%	1	1.3%	2
Histology of Primary	177	97.8%	75	96.2%	252
Total	181	100%	78	100%	259

Table 45 : Number and Relative Proportion of Mouth cancer by Morphology

Broad Histological Classification - Mouth(ICD10: C03-06)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	2	1.1	1.1	4	5.1	4.8
Carcinomas (8010-8035,8041,8050,8052)	6	3.3	3.2	2	2.6	2.4
Verrucous Carcinomas (8051)	7	3.9	3.7	1	1.3	1.2
Squamous Cell Carcinoma (8070 - 8076, 8083 - 8084)	163	90.1	86.2	69	88.5	82.1
Adeno Carcinoma (8140, 8200, 8210, 8251, 8260, 8310, 8525, 8550, 8570)	1	0.6	0.5	-	-	-
Others	2	1.1	1.1	2	2.6	2.4
All Microscopic	181	100.0	95.8	78	100.0	92.9
Non Microscopic	8	-	4.2	6	-	7.1
Total	189	-	100.0	84	-	100.0
* All Microscopic ** Total						

VI NHL

- Total Number (ICD 10: C82-85) : 271 (40.2% females and 59.8% males)
- 6th leading cancer among males and 9th leading cancer among females
- Peak age group: 60-64 years in females and 65-69 males
- Histology : Diffuse Large B-Cell Lymphoma in 33.1 % males and 27.9 % females:
- Method of diagnosis: Microscopic: 99.4% in males and 100% in females
- Detailed Microscopic diagnosis: Histology of Primary: 85.7% in males and 84.4% in females
- Broad treatment group: Treatment only at RI : 45.1% in males and 45.9% in females
- Intention to treat (treatment only at RI): Curative/Radical : 91.8 % in males and 80 % in females
- Composite stage : Stage 4: 24.7% in males and 26.6% in females

Table 46: Number and Relative Proportion of NHL cancer by Five year age group

NHL					
Age	Male	%	Female	%	Total
0-4	1	0.6%	0	0.0%	1
5-9	1	0.6%	1	0.9%	2
10-14	3	1.9%	0	0.0%	3
15-19	0	0.0%	2	1.8%	2
20-24	2	1.2%	4	3.7%	6
25-29	4	2.5%	1	0.9%	5
30-34	7	4.3%	2	1.8%	9
35-39	7	4.3%	9	8.3%	16
40-44	14	8.6%	10	9.2%	24
45-49	12	7.4%	11	10.1%	23
50-54	18	11.1%	10	9.2%	28
55-59	13	8.0%	10	9.2%	23
60-64	25	15.4%	19	17.4%	44
65-69	27	16.7%	15	13.8%	42
70-74	23	14.2%	10	9.2%	33
>=75	5	3.1%	5	4.6%	10
Total	162	100%	109	100%	271

Table 47: Number and Relative Proportion of NHL cancer by Broad treatment group

NHL					
Broad Treatment Group	Male	%	Female	%	Total
No treatment	46	28.4%	31	28.4%	77
Others	10	6.2%	6	5.5%	16
Prior & Treatment at RI	11	6.8%	6	5.5%	17
Prior Treatment Only	22	13.6%	16	14.7%	38
Treatment only at RI	73	45.1%	50	45.9%	123
Total	162	100%	109	100%	271

Table 48: Number and Relative Proportion of NHLcancer by Composite stage

NHL					
Composite stage	Male	%	Female	%	Total
stage1	12	7.4%	8	7.3%	20
stage2	15	9.3%	11	10.1%	26
stage3	28	17.3%	15	13.8%	43
stage4	40	24.7%	29	26.6%	69
Unknown	67	41.4%	46	42.2%	113
Total	162	100%	109	100%	271

Table 49: Number and Relative Proportion of NHLcancer by intention to treat for new patients

NHL					
Intention	Male	%	Female	%	Total
Curative / Radical	67	91.8%	40	80.0%	107
Pain Relief only	0	0.0%	1	2.0%	1
Palliative	6	8.2%	9	18.0%	15
Total	73	100%	50	100%	123

Table 50: Number and Relative Proportion of NHL cancer by Diagnostic status

NHL					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	161	99.4%	109	100.0%	270
Suspected (Microscopically / Radiologically)	1	0.6%	0	0.0%	1
Total	162	100%	109	100%	271

Table 51 : Number and Relative Proportion of NHLcancer by Detailed Microscopic diagnosis

NHL					
Method of diagnosis	Male	%	Female	%	Total
Blood Film	9	5.6%	3	2.8%	12
Bone Marrow	10	6.2%	12	11.0%	22
Cytology of Primary	4	2.5%	2	1.8%	6
Histology of Primary	138	85.7%	92	84.4%	230
Total	161	100%	109	100%	270

Table 52: Number and Relative Proportion of NHL cancer by Morphology

NHL					
Morphology	Male	%	Female	%	Total
Diffuse large B-cell lymphoma	53	33.1%	31	27.9%	84
Non-Hodgkin's lymphoma B-cell	24	15.0%	26	23.4%	50
Polycythaemia Vera	14	8.8%	6	5.4%	20
Myelodysplastic syndrome	12	7.5%	6	5.4%	18
Peripheral T cell lymphoma	11	6.9%	5	4.5%	16
Follicular lymphoma	11	6.9%	15	13.5%	26
Chronic myeloproliferative disorder	4	2.5%	3	2.7%	7
Marginal zone B-cell lymphoma	4	2.5%	3	2.7%	7
Lymphoma -T cell	3	1.9%	2	1.8%	5
Mediastinal large B cell lymphoma	3	1.9%	2	1.8%	5
Mantle cell lymphoma	3	1.9%	1	0.9%	4
Cutaneous T-cell lymphoma	3	1.9%	1	0.9%	4
Burkitt lymphoma	2	1.3%	1	0.9%	3
Myelosclerosis with myeloid metaplasia	2	1.3%	1	0.9%	3
Precursor T-cell lymphoblastic lymphoma	3	1.9%	0	0.0%	3
Others	8	5.0%	8	7.2%	16
Total	160	100%	111	100%	271

VII Stomach

- Total Number (ICD 10: C16) : 260 (26.9% females and 73.1% males)
- Stomach cancer is the 2nd leading site among males.
- Peak age group: 60-64 years in females and 65-69 years in males
- Histology : Adenocarcinoma :59.7 % in males and 44.3 % in females
- Method of diagnosis: Microscopic: 94.7% in males and 95.7% in females
- Detailed Microscopic diagnosis: Histology of Primary: 96.7% in males and 95.5 % in females.
- Broad treatment group: Treatment only at RI: 30% in males and 40% in females
- Clinical extent of disease before treatment (Treatment only at RI) : Direct Extension with Regional Nodes: 31.6 % in males and 32.1 % in females
- Intention to treat (treatment only at RI): Curative: 56.1 % in males and 46.4% in females.
- Composite stage: Stage 4 : 53.7 % in males and 41.4% in females

Table 53: Number and Relative Proportion of Stomach cancer by Five year age group

Stomach					
Age	Male	%	Female	%	Total
25-29	0	0.0%	1	1.4%	1
30-34	1	0.5%	1	1.4%	2
35-39	2	1.1%	5	7.1%	7
40-44	8	4.2%	1	1.4%	9
45-49	12	6.3%	6	8.6%	18
50-54	26	13.7%	8	11.4%	34
55-59	21	11.1%	10	14.3%	31
60-64	29	15.3%	12	17.1%	41
65-69	36	18.9%	8	11.4%	44
70-74	33	17.4%	9	12.9%	42
>=75	22	11.6%	9	12.9%	31
Total	190	100%	70	100%	260

Table 54: Number and Relative Proportion of Stomach cancer by Broad treatment group

Stomach					
Broad treatment group	Male	%	Female	%	Total
No treatment	52	27.4%	16	22.9%	68
Others	37	19.5%	11	15.7%	48
Prior & Treatment at RI	11	5.8%	6	8.6%	17
Prior Treatment Only	33	17.4%	9	12.9%	42
Treatment only at RI	57	30.0%	28	40.0%	85
Total	190	100%	70	100%	260

Table 55: Number and Relative Proportion of Stomach cancer by Clinical extent of disease (Treatment only at RI)

Stomach					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	5	8.8%	2	7.1%	7
Direct Extension with Regional Nodes	18	31.6%	9	32.1%	27
Distant Metastasis	16	28.1%	9	32.1%	25
Localised	11	19.3%	6	21.4%	17
Too Advanced	7	12.3%	2	7.1%	9
Total	57	100%	28	100%	85

Table 56: Number and Relative Proportion of Stomach cancer by Composite stage

Stomach					
Composite stage	Male	%	Female	%	Total
stage1	6	3.2%	3	4.3%	9
stage2	11	5.8%	4	5.7%	15
stage3	23	12.1%	18	25.7%	41
stage4	102	53.7%	29	41.4%	131
Unknown	48	25.3%	16	22.9%	64
Total	190	100%	70	100%	260

Table 57: Number and Relative Proportion of Stomach cancer by intention to treat

Stomach					
Intention	Male	%	Female	%	Total
Curative / Radical	32	56.1%	13	46.4%	45
Palliative	25	43.9%	15	53.6%	40
Total	57	100%	28	100%	85

Table 58: Number and Relative Proportion of Stomach cancer by Diagnostic status

Stomach					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	180	94.7%	67	95.7%	247
Suspected (Microscopically / Radiologically)	10	5.3%	3	4.3%	13
Total	190	100%	70	100%	260

Table 59: Number and Relative Proportion of Stomach cancer by Detailed Microscopic Diagnosis

Stomach					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	0.6%	0	0.0%	1
Cytology of Primary	1	0.6%	0	0.0%	1
Histology of Metastasis	4	2.2%	3	4.5%	7
Histology of Primary	174	96.7%	64	95.5%	238
Total	180	100%	67	100%	247

Table 60: Number and Relative Proportion of Stomach cancer by Morphology

Broad Histological Classification - Stomach(ICD10: C16)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	5	2.8	2.6	3	4.5	4.3
Carcinomas (8010-8035,8041,8070-8072)	21	11.6	11.0	9	13.4	12.9
Adeno Carcinomas (8140,8142-8143, 8144, 8145, 8190, 8240, 8241, 8244, 8246, 8310, 8560, 8570)	114	63.0	59.7	31	46.3	44.3
Mucinous Adeno Carcinoma (8480,8481,8482)	5	2.8	2.6	2	3.0	2.9
Signet Ring Cell Carc(8490)	28	15.5	14.7	14	20.9	20.0
Sarcoma (8800,8801)	-	-	-	-	-	-
Others	8	4.4	4.2	8	11.9	11.4
All Microscopic	181	100.0	94.8	67	100.0	95.7
Non Microscopic	10	-	5.2	3	-	4.3
Total	191	-	100.0	70	-	100.0
* All Microscopic ** Total						

VIII Liver

- Total Number (ICD 10: C22) : 246 (24.8% females and 75.2% males)
- 4th leading cancer among males
- Peak age group: 60-64 years in males and 70-74 in females
- Histology : Hepatocellular carcinoma: 77.3% in males and 47.5% in females
- Method of diagnosis: Microscopic: 28.6% in males and 40.9% in females
- Detailed Microscopic diagnosis: Histology of Primary: 64.2% in males and 52% in females
- Broad treatment group: Treatment only at RI : 24.9% in males and 23% in females
- Clinical extent of disease before treatment (Treatment only at RI): Direct Extension: 28.3% in males and 7.1% in females.
- Intention to treat (treatment only at RI): Curative : 17.4% in males and 35.7% in females.
- Composite Stage: Stage 4 : 40% in males and 42.6% in females

Table 61: Number and Relative Proportion of liver cancer by Five year age group

Liver					
Age	Male	%	Female	%	Total
0-4	1	0.5%	0	0.0%	1
10-14	0	0.0%	1	1.6%	1
20-24	0	0.0%	1	1.6%	1
30-34	0	0.0%	1	1.6%	1
35-39	1	0.5%	1	1.6%	2
40-44	5	2.7%	2	3.3%	7
45-49	5	2.7%	2	3.3%	7
50-54	9	4.9%	3	4.9%	12
55-59	27	14.6%	5	8.2%	32
60-64	45	24.3%	11	18.0%	56
65-69	43	23.2%	9	14.8%	52
70-74	31	16.8%	12	19.7%	43
>=75	18	9.7%	13	21.3%	31
Total	185	100%	61	100%	246

Table 62: Number and Relative Proportion of liver cancer by Broad treatment group

Liver					
Broad Treatment Group	Male	%	Female	%	Total
No treatment	92	49.7%	32	52.5%	124
Others	25	13.5%	7	11.5%	32
Prior & Treatment at RI	6	3.2%	0	0.0%	6
Prior Treatment Only	16	8.6%	8	13.1%	24
Treatment only at RI	46	24.9%	14	23.0%	60
Total	185	100%	61	100%	246

Table 63 : Number and Relative Proportion of liver cancer by Clinical extent of disease before treatment (Treatment only at RI)

Liver					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	13	28.3%	1	7.1%	14
Direct Extension with Regional Nodes	3	6.5%	1	7.1%	4
Distant Metastasis	10	21.7%	10	71.4%	20
Localised	11	23.9%	1	7.1%	12
Too Advanced	9	19.6%	1	7.1%	10
Total	46	100%	14	100%	60

Table 64: Number and Relative Proportion of liver cancer by composite stage

Liver					
Composite stage	Male	%	Female	%	Total
stage1	2	1.1%	0	0.0%	2
stage2	1	0.5%	0	0.0%	1
stage3	9	4.9%	2	3.3%	11
stage4	74	40.0%	26	42.6%	100
Unknown	99	53.5%	33	54.1%	132
Total	185	100%	61	100%	246

Table 65 : Number and Relative Proportion of liver cancer by intention to treat

Liver (Treatment only at RI)					
Intention	Male	%	Female	%	Total
Curative / Radical	8	17.4%	5	35.7%	13
Palliative	38	82.6%	9	64.3%	47
Total	46	100%	14	100%	60

Table 66 : Number and Relative Proportion of liver cancer by Diagnostic status

Liver					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	53	28.6%	25	40.9%	78
No registered at RI	0	0.0%	1	1.6%	1
Suspected (Microscopically / Radiologically)	132	71.4%	35	57.4%	167
Total	185	100%	61	100%	246

Table 67 : Number and Relative Proportion of liver cancer by Detailed Microscopicniosis

Liver					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	1	1.9%	0	0.0%	1
Cytology of Primary	1	1.9%	1	4.0%	2
Histology of Metastasis	17	32.1%	11	44.0%	28
Histology of Primary	34	64.2%	13	52.0%	47
Total	53	100%	25	100%	78

Table 68: Number and Relative Proportion of liver cancer by Morphology

Liver					
Morphology.	Male	%	Female	%	Total
Hepatocellular ca	143	77.3%	29	47.5%	172
Neoplasm malignant	33	17.8%	21	34.4%	54
Cholangiocarcinoma	6	3.2%	5	8.2%	11
Adenocarcinoma	1	0.5%	5	8.2%	6
Hepatoblastoma	1	0.5%	0	0.0%	1
Squamous cell carcinoma	1	0.5%	0	0.0%	1
Carcinoma	0	0.0%	1	1.6%	1
Total	185	100%	61	100%	246

IX Colon

- Total Number (ICD 10: C18) : 234(48.7% females and 51.3% males)
- 10th leading cancer among males and 8th leading cancer among females.
- Peak age group: 60-64 years in males and in females
- Histology : Adenocarcinoma: 67.2 % in males and 66.7 % in females
- Method of diagnosis: Microscopic: 86.7% in males and 92.1% in females
- Detailed Microscopic diagnosis: Histology of Primary : 92.3% in males and 93.3% in females
- Broad treatment group: Treatment only at RI : 25.8% in males and 30.7 % in females
- Clinical extent of disease before treatment (Treatment only at RI):Distant Metastasis: 35.5% in males and 31.4% in females
- Intention to treat (treatment only at RI):: Curative/Radical : 67.7% in males and 85.7% in females
- Composite Stage: Stage 4: 46.7 % in males and 42.1 % in females

Table 69: Number and Relative Proportion of Colon cancer by Five year age group

Colon					
Age	Male	%	Female	%	Total
25-29	1	0.8%	1	0.9%	2
30-34	1	0.8%	4	3.5%	5
35-39	4	3.3%	3	2.6%	7
40-44	4	3.3%	8	7.0%	12
45-49	13	10.8%	11	9.6%	24
50-54	12	10.0%	12	10.5%	24
55-59	13	10.8%	14	12.3%	27
60-64	24	20.0%	23	20.2%	47
65-69	19	15.8%	13	11.4%	32
70-74	16	13.3%	14	12.3%	30
>=75	13	10.8%	11	9.6%	24
Total	120	100%	114	100%	234

Table 70: Number and Relative Proportion of Colon cancer by Broad Treatment Group

Colon			Female	%	Total
Broad Treatment Group	Male	%			
No treatment	28	23.3%	25	21.9%	53
Others	14	11.7%	12	10.5%	26
Prior & Treatment at RI	19	15.8%	21	18.4%	40
Prior Treatment Only	28	23.3%	21	18.4%	49
Treatment only at RI	31	25.8%	35	30.7%	66
Total	120	100%	114	100%	234

Table 71 : Number and Relative Proportion of Colon cancer by Clinical extent of disease before treatment (Treatment only at RI)

Colon			Female	%	Total
Clinical extent before treatment	Male	%			
Direct Extension	7	22.6%	4	11.4%	11
Direct Extension with Regional Nodes	5	16.1%	7	20.0%	12
Distant Metastasis	11	35.5%	11	31.4%	22
Localised	8	25.8%	13	37.1%	21
Total	31	100%	35	100%	66

Table 72: Number and Relative Proportion of Colon cancer by Composite Stage

Colon					
composite stage	Male	%	Female	%	Total
stage1	6	5.0%	5	4.4%	11
stage2	13	10.8%	16	14.0%	29
stage3	26	21.7%	28	24.6%	54
stage4	56	46.7%	48	42.1%	104
Unknown	19	15.8%	17	14.9%	36
Total	120	100%	114	100%	234

Table 73 : Number and Relative Proportion of Colon cancer by Intention to treat

Colon					
Intention	Male	%	Female	%	Total
Curative / Radical	21	67.7%	30	85.7%	51
Palliative	10	32.3%	4	11.4%	14
Symptomatic	0	0.0%	1	2.9%	1
Total	31	100%	35	100%	66

Table 74: Number and Relative Proportion of Colon cancer by Diagnostic Status

Colon					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	104	86.7%	105	92.1%	209
Suspected (Microscopically / Radiologically)	16	13.3%	9	7.9%	25
Total	120	100%	114	100%	234

Table 75 : Number and Relative Proportion of Colon cancer by Detailed Microscopic Diagnosis

Colon					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	0	0.0%	2	1.9%	2
Cytology of Primary	0	0.0%	1	1.0%	1
Histology of Metastasis	8	7.7%	4	3.8%	12
Histology of Primary	96	92.3%	98	93.3%	194
Total	104	100%	105	100%	209

Table 76 : Number and Relative Proportion of Colon cancer by Morphology

WHO Histological Classification - Colon(ICD10: C18)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Adenocarcinoma (8140)	82	77.4	67.2	76	72.4	66.7
Mucinous adenocarcinoma (8480)	10	9.4	8.2	17	16.2	14.9
Signet-ring cell carcinoma (8490)	9	8.5	7.4	4	3.8	3.5
Small cell carcinoma (8041)	1	0.9	0.8	-	-	-
Leiomyoma (8890)	-	-	-	1	1.0	0.9
Burkitt lymphoma (9687)	1	0.9	0.8	-	-	-
Others	3	2.8	2.5	7	6.7	6.1
All Microscopic	106	100.0	86.9	105	100.0	92.1
Non Microscopic	16	-	13.1	9	-	7.9
Total	122	-	100.0	114	-	100.0
* All Microscopic ** Total						

X Tongue

- Total Number (ICD 10: C01-02) : 177 (29.4% females and 70.6 % males)
- 9th leading cancer among males
- Peak age group: 45-49 years in males and 65-69 in females
- Histology : Squamous cell Carcinoma: 92.8 % in males and 88.5 % in females
- Method of diagnosis: Microscopic: 98.4% in males and 98.1% in females
- Detailed Microscopic diagnosis: Histology of Primary : 95.1% in males and 98 % in females
- Broad treatment group: Treatment only at RI : 64% in males and 67.3 % in females
- Clinical extent of disease before treatment (Treatment only at RI): Localised: 51.3% in males and 54.3% in females
- Intention to treat (treatment only at RI) : Curative/Radical : 78.8% in males and 74.3% in females
- Composite Stage: Stage 4: 33.6 % in males and 28.8 % in females

Table 77: Number and Relative Proportion of Tongue cancer by Five year age group

Tongue					
Age	Male	%	Female	%	Total
Age	Male	%	Female	%	Total
25-29	2	1.6%	0	0.0%	2
30-34	6	4.8%	2	3.8%	8
35-39	7	5.6%	1	1.9%	8
40-44	8	6.4%	1	1.9%	9
45-49	18	14.4%	3	5.8%	21
50-54	18	14.4%	6	11.5%	24
55-59	17	13.6%	2	3.8%	19
60-64	17	13.6%	8	15.4%	25
65-69	13	10.4%	11	21.2%	24
70-74	10	8.0%	6	11.5%	16
>=75	9	7.2%	12	23.1%	21
Total	125	100%	52	100%	177

Table 78: Number and Relative Proportion of Tongue cancer by Broad Treatment Group

Tongue					
Broad Treatment Group	Male	%	Female	%	Total
No treatment	6	4.8%	3	5.8%	9
Others	15	12.0%	7	13.5%	22
Prior & Treatment at RI	11	8.8%	4	7.7%	15
Prior Treatment Only	13	10.4%	3	5.8%	16
Treatment only at RI	80	64.0%	35	67.3%	115
Total	125	100%	52	100%	177

Table 79 : Number and Relative Proportion of Tongue cancer by Clinical extent of disease before treatment (Treatment only at RI)

Tongue					
Clinical extent before treatment	Male	%	Female	%	Total
Direct Extension	6	7.5%	4	11.4%	10
Direct Extension with Regional Nodes	26	32.5%	7	20.0%	33
Localised	41	51.3%	19	54.3%	60
Recurrent	0	0.0%	1	2.9%	1
Too Advanced	7	8.8%	4	11.4%	11
Total	80	100%	35	100%	115

Table 80: Number and Relative Proportion of Tongue cancer by Composite Stage

Tongue					
composite stage	Male	%	Female	%	Total
stage1	21	16.8%	10	19.2%	31
stage2	32	25.6%	17	32.7%	49
stage3	30	24.0%	10	19.2%	40
stage4	42	33.6%	15	28.8%	57
Total	125	100%	52	100%	177

Table 81 : Number and Relative Proportion of Tongue cancer by Intention to treat

Tongue (Treatment only at RI)					
intention	Male	%	Female	%	Total
Curative / Radical	63	78.8%	26	74.3%	89
Palliative	17	21.3%	9	25.7%	26
Total	80	100%	35	100%	115

Table 82 : Number and Relative Proportion of Tongue cancer by Diagnostic Status

Tongue					
Diagnostic status	Male	%	Female	%	Total
Microscopically Confirmed	123	98.4%	51	98.1%	174
No registered at RI	1	0.8%	0	0.0%	1
Suspected (Clinically / To rule out Malignancy)	1	0.8%	0	0.0%	1
Suspected (Microscopically / Radiologically)	0	0.0%	1	1.9%	1
Total	125	100%	52	100%	177

Table 83 : Number and Relative Proportion of Tongue cancer by Detailed Microscopic Diagnosis

Tongue					
Method of diagnosis	Male	%	Female	%	Total
Cytology of Metastasis	4	3.3%	1	2.0%	5
Cytology of Primary	2	1.6%	0	0.0%	2
Histology of Primary	117	95.1%	50	98.0%	167
Total	123	100%	51	100%	174

Table 84 : Number and Relative Proportion of Tongue cancer by Morphology

Broad Histological Classification - Tongue(ICD10: C01-02)Number (#) and Relative Proportion (%) of Different Histologic Types(Report from NCDIR/ICMR)

Histologic Type	Males			Females		
	#	%*	%**	#	%*	%**
Neoplasm Malignant (8000-8005,9990)	3	2.4	2.4	1	2.0	1.9
Carcinomas (8010-8035,8041,8046)	2	1.6	1.6	-	-	-
Verrucous Carcinomas (8051)	2	1.6	1.6	2	3.9	3.8
SquamousCellCarcinoma(8052,8070-8076,8083-8084)	116	94.3	92.8	46	90.2	88.5
Adeno Carcinoma (8140,8200,8525,8560)	-	-	-	2	3.9	3.8
All Microscopic	123	100.0	98.4	51	100.0	98.1
Non Microscopic	2	-	1.6	1	-	1.9
Total	125	-	100.0	52	-	100.0
* All Microscopic ** Total						

REFERENCES:

1. Isabel dos Santos Silva (1999), Cancer Epidemiology, Principles and Methods IARC Publications, France.
2. Maclennan et al (1978) Cancer Registration and its Techniques IARC Scientific Publications No.21 France.
3. Young J.L (1991) Hospital Based Cancer Registry in Cancer Registration Principles and Methods IARC Publications France.
4. April Fritz, Constance Percy et al. International Classification of Disease for Oncology Third Edition, World Health Organization Geneva 2000.
5. John L. Young, Steven D. Roffers et al, seer summary staging manual 2000 codes and coding instruction
6. Hospital Based Cancer Registry Report, Regional Cancer Centre published by Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Thiruvananthapuram June 2020.